CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
11695249,116952494,4,F,20090930,20181108,20151103,20181119,EXP,FR-EMA-20130214-MMEVHUMANWT-150034270,FR-009507513-0906USA00645,MERCK,,19,YR,,F,Y,,,20181119,,CN,FR,FR,SUSTIVA,Caesarean section;Drug ineffective;Drug interaction;Maternal exposure during pregnancy;Normal newborn;Pregnancy on contraceptive;Unintended pregnancy,116952494,OT,,,116952494,1,20080215,,,,116952494,1,Product used for unknown indication
11702440,117024405,5,F,20151021,20181018,20151105,20181023,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-074328,BRISTOL MYERS SQUIBB,,31,YR,,M,Y,,,20181023,,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Bacterial sepsis;Renal failure,117024405,HO,,,117024405,1,20150527,20150916,,,117024405,1,Kaposi's sarcoma AIDS related
11858629,118586296,6,F,,20181029,20151222,20181109,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2007-000002,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181109,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Heart disease congenital,118586296,CA,,,118586296,1,20051201,20071211,,,118586296,1,Product used for unknown indication
11868354,118683548,8,F,20001221,20181026,20151224,20181107,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-11527520,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20181107,,OT,FR,FR,EFAVIRENZ.,Gestational diabetes;Normal newborn;Pregnancy,118683548,OT,,,118683548,1,19970902,,,,118683548,1,Antiretroviral therapy
12596893,125968932,2,F,,20181127,20160727,20181210,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-061580,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20181210,,OT,ZA,GB,EFAVIRENZ.,Autoimmune hepatitis,125968932,OT,,,,,,,,,125968932,1,HIV infection
12808467,128084673,3,F,2006,20180721,20161004,20181008,EXP,,US-DSJP-DSU-2016-115237,DAIICHI,,,,,,Y,,,20181005,,MD,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;Colectomy;Intestinal obstruction;Large intestine polyp;Peritonitis;Sprue-like enteropathy,128084673,HO,,,128084673,1,2003,201205,,,128084673,1,Hypertension
13274205,1327420510,10,F,,20181206,20170227,20181219,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-016053,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20181219,,CN,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,1327420510,OT,,,1327420510,1,201110,,,,1327420510,1,HIV infection
14017096,140170963,3,F,20170509,20181129,20170927,20181206,EXP,,UG-MYLANLABS-2017M1058627,MYLAN,,,,,M,Y,3,KG,20181206,,OT,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Stillbirth,140170963,OT,,,140170963,1,20170309,20170313,,,140170963,1,HIV infection
14017101,140171012,2,F,,20181129,20170927,20181210,EXP,,UG-MYLANLABS-2017M1058622,MYLAN,,,,,M,Y,3,KG,20181210,,OT,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly;Syndactyly,140171012,CA,,,140171012,1,20170530,,,,140171012,1,HIV infection
14132606,141326063,3,F,,20171031,20171027,20181224,EXP,,FR-CIPLA LTD.-2017FR18490,CIPLA,,,,,,Y,,,20181224,,CN,FR,FR,EFAVIRENZ.,Exposure during pregnancy;Headache;Hypertension;Metrorrhagia,141326063,HO,,,141326063,2,20150608,20150608,,,141326063,1,HIV infection
14165463,1416546310,10,F,201404,20181128,20171107,20181211,EXP,,IT-AUROBINDO-AUR-APL-2017-43260,AUROBINDO,,27,YR,,F,Y,,,20181212,,OT,IT,IT,Efavirenz Film Coated Tablets,Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,1416546310,OT,,,1416546310,7,201505,,,,1416546310,1,Antiretroviral therapy
14246609,142466096,6,F,,20181024,20171204,20181105,EXP,,GB-AUROBINDO-AUR-APL-2017-43959,AUROBINDO,,85,YR,,M,Y,,,20181105,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,142466096,OT,,,,,,,,,142466096,1,Cardiovascular event prophylaxis
14247661,1424766110,10,F,,20181121,20171204,20181127,EXP,,GB-009507513-1711GBR010764,MERCK,,85,YR,,M,Y,,,20181127,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,1424766110,OT,,,,,,,,,1424766110,1,Cardiovascular event prophylaxis
14254383,1425438311,11,F,,20181008,20171205,20181010,EXP,,GB-TEVA-2017-GB-828487,TEVA,,85,YR,,M,Y,,,20181010,,MD,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,1425438311,OT,,,,,,,,,1425438311,1,Cardiovascular event prophylaxis
14263156,142631569,9,F,,20181115,20171208,20181128,EXP,GB-MHRA-ADR 24247007,GB-LUPIN PHARMACEUTICALS INC.-2017-07065,LUPIN,,85,YR,,M,Y,,,20181128,,CN,GB,GB,EFAVIRENZ.,Contraindicated product prescribed;Drug interaction;Renal impairment,142631569,OT,,,,,,,,,142631569,1,Cardiovascular event prophylaxis
14283035,142830353,3,F,20071025,20181031,20171213,20181109,EXP,,FR-GILEAD-2017-0310074,GILEAD,,,,,F,Y,,,20181109,,CN,GB,FR,SUSTIVA,Foetal exposure during pregnancy;Heart disease congenital,142830353,OT,,,142830353,1,20071025,20071211,,,142830353,1,Antiretroviral therapy
14323370,143233703,3,F,,20171214,20171226,20181224,EXP,,IN-CIPLA LTD.-2017IN29074,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143233703,OT,,,,,,,,,143233703,1,Antiretroviral therapy
14323371,143233712,2,F,,20171214,20171226,20181224,EXP,,IN-CIPLA LTD.-2017IN29072,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE-VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Death,143233712,DE,,,,,,,,,143233712,1,Antiretroviral therapy
14334853,143348532,2,F,,20171214,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29080,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE-VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143348532,DE,,,,,,,,,143348532,1,HIV infection
14334866,143348662,2,F,,20171214,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29071,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE-VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181220,,OT,IN,IN,EFAVIRENZ.,Death,143348662,DE,,,,,,,,,143348662,1,Antiretroviral therapy
14335012,143350122,2,F,,20171214,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN28885,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Death,143350122,DE,,,,,,,,,143350122,1,Antiretroviral therapy
14335017,143350172,2,F,,20171214,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29078,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143350172,OT,,,,,,,,,143350172,1,HIV infection
14335018,143350182,2,F,,20171214,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29084,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143350182,OT,,,,,,,,,143350182,1,Antiretroviral therapy
14335021,143350212,2,F,,20171214,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29081,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Death,143350212,DE,,,,,,,,,143350212,1,HIV infection
14335022,143350222,2,F,,20171214,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29075,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181220,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143350222,OT,,,,,,,,,143350222,1,Antiretroviral therapy
14335024,143350242,2,F,,20171214,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29089,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181220,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143350242,OT,,,,,,,,,143350242,1,HIV infection
14335025,143350252,2,F,,20171214,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29083,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143350252,OT,,,,,,,,,143350252,1,Antiretroviral therapy
14335057,143350572,2,F,,20171214,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29087,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143350572,OT,,,,,,,,,143350572,1,Antiretroviral therapy
14335518,143355182,2,F,,20171214,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29088,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143355182,DE,,,,,,,,,143355182,1,Antiretroviral therapy
14335522,143355222,2,F,,20171214,20171229,20181224,EXP,,IN-CIPLA LTD.-2017IN29076,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143355222,OT,,,,,,,,,143355222,1,Antiretroviral therapy
14335523,143355232,2,F,,20171214,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29085,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17 (761):1 TO 8",,,,,Y,,,20181220,,OT,IN,IN,EFAVIRENZ.,Treatment failure,143355232,OT,,,,,,,,,143355232,1,Antiretroviral therapy
14335525,143355252,2,F,,20171214,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29082,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE-VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181220,,OT,IN,IN,EFAVIRENZ.,Death,143355252,DE,,,,,,,,,143355252,1,Antiretroviral therapy
14335535,143355352,2,F,,20171214,20171229,20181220,EXP,,IN-CIPLA LTD.-2017IN29079,CIPLA,"SINHA S, GUPTA K, TRIPATHY S, DHOORIA S, RANJAN S, PANDEY RM. NEVIRAPINE- VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY REGIMENS IN ANTIRETROVIRAL-NAIVE PATIENTS WITH HIV AND TUBERCULOSIS INFECTIONS IN INDIA: A MULTI-CENTRE STUDY. BMC INFECTIOUS DISEASES. 2017;17:761:1 TO 8",,,,,Y,,,20181220,,OT,IN,IN,EFAVIRENZ.,Death;Treatment failure,143355352,OT,,,,,,,,,143355352,1,HIV infection
14339631,143396315,5,F,,20181013,20171230,20181026,EXP,,GB-AUROBINDO-AUR-APL-2017-48435,AUROBINDO,,,,C,,Y,,,20181026,,OT,GB,GB,Efavirenz Film-coated Tablet,Cognitive disorder;Diplegia;Disturbance in attention;Enuresis;Fatigue;Gynaecomastia;HIV-associated neurocognitive disorder;Headache;Hypercholesterolaemia;Mood altered;Psychotic disorder;Sleep disorder;Stevens-Johnson syndrome;Virologic failure,143396315,OT,,,,,,,,,143396315,1,Perinatal HIV infection
14344346,143443463,3,F,,20181214,20180102,20181218,EXP,,GB-MYLANLABS-2017M1083674,MYLAN,"WYNBERG E, WILLIAMS E, TUDOR-WILLIAMS G, LYALL H, FOSTER C.. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLIN DRUG INVESTIG.. 2018;38 (3):231-8",,,C,,Y,,,20181218,,OT,GB,GB,EFAVIRENZ.,Disturbance in attention;Enuresis;Fatigue;Gynaecomastia;Headache;Hypercholesterolaemia;Mood altered;Psychotic disorder;Sleep disorder;Stevens-Johnson syndrome;Virologic failure,143443463,OT,,,,,,,,,143443463,1,Product used for unknown indication
14355025,143550255,5,F,,20181009,20180105,20181022,EXP,,GB-AUROBINDO-AUR-APL-2018-000089,AUROBINDO,,85,YR,,M,Y,,,20181022,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,143550255,OT,,,,,,,,,143550255,1,Cardiovascular event prophylaxis
14361836,143618362,2,F,,20171226,20180108,20181220,EXP,,US-CIPLA LTD.-2017US30878,CIPLA,,,,,,Y,,,20181220,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143618362,OT,,,,,,,,,143618362,1,HIV infection
14361837,143618372,2,F,,20171226,20180108,20181224,EXP,,US-CIPLA LTD.-2017US30879,CIPLA,,,,,,Y,,,20181224,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143618372,OT,,,,,,,,,143618372,1,HIV infection
14362161,143621612,2,F,,20171226,20180108,20181224,EXP,,US-CIPLA LTD.-2017US30912,CIPLA,,,,,,Y,,,20181224,,OT,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Premature baby,143621612,OT,,,,,,,,,,,
14363782,143637825,5,F,201404,20181129,20180108,20181212,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-098391,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20181212,,OT,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,143637825,OT,,,,,,,,,143637825,1,HIV infection
14367906,143679064,4,F,2015,20181019,20180109,20181026,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-118541,BRISTOL MYERS SQUIBB,,56,YR,,M,Y,57,KG,20181026,,MD,FR,FR,SUSTIVA,General physical health deterioration;Hypermetabolism;Pulmonary mass;Virologic failure,143679064,HO,,,143679064,3,20151117,,,,143679064,1,HIV infection
14462981,144629814,4,F,,20181115,20180130,20181119,EXP,,GB-ALLERGAN-1771124US,ALLERGAN,,85,YR,,M,Y,,,20181119,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,144629814,OT,,,,,,,,,144629814,1,Inflammatory bowel disease
14474585,144745854,4,F,20171107,20180920,20180201,20180925,EXP,GB-MHRA-EYC 00171403,GB-MYLANLABS-2018M1006020,MYLAN,,47,YR,,F,Y,,,20180925,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,144745854,OT,,,144745854,1,20170501,20171216,,,144745854,1,HIV infection
14475215,144752159,9,F,,20180503,20180201,20181207,EXP,,IE-SA-2017SA124549,SANOFI AVENTIS,,37,YR,A,F,Y,,,20181207,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective;Leukopenia;Off label use;Skin atrophy,144752159,OT,,,,,,,,,144752159,1,Cutaneous sarcoidosis
14495878,144958783,3,F,,20180124,20180207,20181224,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA02656,CIPLA,"SCRIVEN JE, BOTHA FCJ, SCHUTZ C, LALLOO DG, WAINWRIGHT H, MEINTJES G. PARADOXICAL RESPIRATORY FAILURE DUE TO CRYPTOCOCCAL PNEUMONIA AFTER AMPHOTERICIN B TREATMENT FOR HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:38 TO 40",,,,,Y,,,20181224,,OT,ZA,ZA,EFAVIRENZ.,Anaemia macrocytic;Meningitis cryptococcal;Pneumonia cryptococcal;Respiratory failure,144958783,HO,,,,,,,,,144958783,1,HIV infection
14527089,145270897,7,F,,20180924,20180213,20181001,EXP,,IE-MYLANLABS-2018M1009569,MYLAN,,37,YR,,F,Y,,,20181001,,OT,GB,IE,EFAVIRENZ.,Cushingoid;Drug ineffective for unapproved indication;Leukopenia;Off label use;Skin atrophy,145270897,OT,,,,,,,,,145270897,1,Sarcoidosis
14544345,145443453,3,F,20180209,20181121,20180216,20181202,EXP,,BR-ABBVIE-18P-020-2255672-00,ABBVIE,,31,YR,,F,Y,,,20181202,,OT,BR,BR,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,145443453,OT,,,145443453,1,20180103,20180103,,,145443453,1,HIV infection
14586226,145862262,2,F,20170606,20181121,20180301,20181207,EXP,,UG-MYLANLABS-2018M1012525,MYLAN,,26,YR,,F,Y,,,20181207,,OT,UG,UG,TENOFOVIR DF/LAMIVUDINE/EFAVIRENZ TABLETS 300/300/600MG,Malaria;Maternal exposure during pregnancy;Stillbirth,145862262,OT,,,145862262,1,20170118,,,,145862262,1,HIV infection
14662859,146628592,2,F,,20180306,20180321,20181011,EXP,,TH-NOVITIUM PHARMA LLC-2018-TH-000005,NOVITIUM PHARMA,"TEMPARK T, SATAPORNPONG P, RERKNIMITR P, NAKKAM N, SAKSIT N, WATTANAKRAI P, ET AL..DAPSONE-INDUCED SEVERE CUTANEOUS ADVERSE DRUG REACTIONS ARE STRONGLY LINKED WITH HLA-B*13:01 ALLELE IN THE THAI POPULATION.PHARMACOGENETICS AND GENOMICS.2017;27(12):429-437.",57,YR,A,F,Y,,,20181011,,,TH,TH,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms;Hepatitis;Leukocytosis;Product use in unapproved indication;Purpura;Pyrexia;Rash maculo-papular;Skin exfoliation,146628592,LT,,,,,,,,,146628592,1,Prophylaxis against HIV infection
14662894,146628942,2,F,,20180306,20180321,20181011,EXP,,TH-NOVITIUM PHARMA LLC-2018-TH-000010,NOVITIUM PHARMA,"TEMPARK T, SATAPORNPONG P, RERKNIMITR P, NAKKAM N, SAKSIT N, WATTANAKRAI P, ET AL..DAPSONE-INDUCED SEVERE CUTANEOUS ADVERSE DRUG REACTIONS ARE STRONGLY LINKED WITH HLA-B*13:01 ALLELE IN THE THAI POPULATION?.PHARMACOGENETICS AND GENOMICS.2017;27(12):429-437.",56,YR,A,M,Y,,,20181011,,,TH,TH,Efavirenz/tenofovir/emtricitabine,Drug reaction with eosinophilia and systemic symptoms;Hepatitis;Mouth ulceration;Papule;Product use in unapproved indication;Pyrexia,146628942,LT,,,,,,,,,146628942,1,Pneumocystis jirovecii pneumonia
14662921,146629212,2,F,,20180306,20180321,20181011,EXP,,TH-NOVITIUM PHARMA LLC-2018-TH-000014,NOVITIUM PHARMA,"TEMPARK T, SATAPORNPONG P, RERKNIMITR P, NAKKAM N, SAKSIT N, WATTANAKRAI P, ET AL.DAPSONE-INDUCED SEVERE CUTANEOUS ADVERSE DRUG REACTIONS ARE STRONGLY LINKED WITH HLA-B*13:01 ALLELE IN THE THAI POPULATION.PHARMACOGENETICS AND GENOMICS.2017;27(12):429-437.",41,YR,A,M,Y,,,20181011,,,TH,TH,EFAVIRENZ.,Hepatitis;Product use in unapproved indication;Purpura;Pyrexia;Rash maculo-papular;Skin exfoliation;Stevens-Johnson syndrome,146629212,LT,,,,,,,,,146629212,1,Prophylaxis against HIV infection
14666305,146663054,4,F,,20180403,20180321,20181109,EXP,FR-EMA-20170404-RENITAROYP-155219665,FR-GILEAD-2016-0216062,GILEAD,,28,YR,A,F,Y,,,20181109,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,146663054,OT,,,146663054,1,201110,,,,146663054,1,HIV infection
14715497,147154972,2,F,,20181008,20180404,20181118,EXP,,FR-MYLANLABS-2018M1020400,MYLAN,,28,YR,,F,Y,,,20181118,,CN,US,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,147154972,OT,,,,,,,,,147154972,1,HIV infection
14758880,147588802,2,F,,20181017,20180413,20181023,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2018058111,VIIV,LYALL H. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLIN DRUG INVESTIG. 2018;38(3):231-8,,,C,,Y,,,20181023,,OT,GB,GB,EFAVIRENZ.,Disturbance in attention;Enuresis;Fatigue;Gynaecomastia;Headache;Hypercholesterolaemia;Mood altered;Psychotic disorder;Sleep disorder;Stevens-Johnson syndrome;Virologic failure,147588802,OT,,,,,,,,,147588802,1,Perinatal HIV infection
14758881,147588812,2,F,,20181017,20180413,20181023,EXP,,GB-GLAXOSMITHKLINE-GB2018058111,GLAXOSMITHKLINE,LYALL H. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLIN DRUG INVESTIG. 2018;38(3):231-8,,,C,,Y,,,20181023,,OT,GB,GB,EFAVIRENZ.,Disturbance in attention;Enuresis;Fatigue;Gynaecomastia;Headache;Hypercholesterolaemia;Mood altered;Psychotic disorder;Sleep disorder;Stevens-Johnson syndrome;Virologic failure,147588812,OT,,,,,,,,,147588812,1,Perinatal HIV infection
14759551,147595512,2,F,,20180921,20180413,20181001,EXP,,DE-GLAXOSMITHKLINE-DE2017193261,GLAXOSMITHKLINE,LIEBERT U. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES.. A DECADE LONGITUDINAL STUDY. 2017;12:10,25,YR,,F,Y,,,20181001,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Viral mutation identified,147595512,OT,,,,,,,,,147595512,1,Product used for unknown indication
14759552,147595522,2,F,,20180921,20180413,20181001,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2017193261,VIIV,LIEBERT U. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES.. A DECADE LONGITUDINAL STUDY. 2017;12:10,25,YR,,F,Y,,,20181001,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Viral mutation identified,147595522,OT,,,,,,,,,147595522,1,Product used for unknown indication
14773305,147733052,2,F,,20180919,20180418,20181003,EXP,,DE-AUROBINDO-AUR-APL-2017-47616,AUROBINDO,,25,YR,,F,Y,,,20181003,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,147733052,OT,,,,,,,,,147733052,1,Product used for unknown indication
14868582,148685823,3,F,20180413,20181122,20180509,20181127,EXP,,BR-STRIDES ARCOLAB LIMITED-2018SP003477,STRIDES,,1,MON,,F,Y,,,20181127,,OT,BR,BR,EFAVIRENZ.,Foetal exposure during pregnancy;Genitalia external ambiguous,148685823,CA,,,,,,,,,148685823,1,Product used for unknown indication
14894776,148947766,6,F,2002,20181205,20180515,20181218,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041488,BRISTOL MYERS SQUIBB,,55,YR,,M,Y,,,20181218,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,148947766,HO,,,148947766,5,1997,,,,148947766,1,HIV infection
14898979,148989792,2,F,,20180928,20180515,20181005,EXP,,PHHY2018FR025038,SANDOZ,,54,YR,,M,Y,,,20181005,,OT,FR,FR,EFAVIRENZ.,Drug ineffective;Haematotoxicity;Hepatitis C,148989792,OT,,,148989792,5,200709,200804,,,148989792,1,Acquired haemophilia
14933630,149336302,2,F,,20180920,20180524,20181005,EXP,,GB-AUROBINDO-AUR-APL-2018-027236,AUROBINDO,,,,I,,Y,,,20181005,,OT,GB,GB,Efavirenz Film-coated Tablet,Exposure via breast milk;Foetal exposure during pregnancy;Polydactyly,149336302,CA,,,,,,,,,149336302,1,Product used for unknown indication
14936059,149360592,2,F,20170908,20181126,20180524,20181203,EXP,,ZA-GILEAD-2018-0339854,GILEAD,,,,,F,Y,,,20181203,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Pre-eclampsia;Premature delivery,149360592,OT,,,149360592,1,20170908,20171105,,,149360592,1,HIV infection
14936127,149361272,2,F,20170908,20181126,20180524,20181203,EXP,,ZA-GILEAD-2018-0339857,GILEAD,,,,N,F,Y,,,20181203,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocephalus;Neonatal respiratory distress,149361272,OT,,,149361272,1,20170908,20171105,,,149361272,1,HIV infection
14937462,149374622,2,F,,20181005,20180525,20181018,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-043920,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20181018,,OT,GB,GB,EFAVIRENZ.,Gestational hypertension;Live birth;Maternal exposure during pregnancy;Product use issue,149374622,OT,,,,,,,,,149374622,1,HIV infection
14986565,149865652,2,F,2015,20181101,20180608,20181112,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-049452,BRISTOL MYERS SQUIBB,,,,,M,Y,105,KG,20181112,,MD,FR,FR,SUSTIVA,Condition aggravated;Hepatitis,149865652,OT,,,149865652,1,2005,,,,149865652,1,HIV infection
14992306,149923065,5,F,,20181121,20180608,20181130,EXP,,BR-ABBVIE-18S-020-2379837-00,ABBVIE,,,,,F,Y,2.25,KG,20181130,,OT,BR,BR,LAMIVUDINE+EFAVIRENZ+TENOFO,Congenital genital malformation female;Foetal exposure during pregnancy,149923065,CA,,,,,,,,,149923065,1,Maternal exposure timing unspecified
15009609,150096092,2,F,,20180919,20180614,20181001,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-050860,BRISTOL MYERS SQUIBB,,55,YR,,M,Y,,,20181001,,MD,GB,GB,EFAVIRENZ.,Toxicity to various agents,150096092,DE,,,,,,,,,150096092,1,HIV infection
15016011,150160115,5,F,20180603,20181106,20180615,20181112,EXP,,FR-BEH-2018091357,CSL BEHRING,,59,YR,A,M,Y,,,20181112,,CN,FR,FR,EFAVIRENZ.,Peripheral ischaemia,150160115,DS,,,150160115,1,20180501,20180604,,,150160115,1,Factor IX deficiency
15017665,150176652,2,F,20110914,20181115,20180615,20181122,EXP,,GB-JNJFOC-20111001501,JANSSEN,,15,YR,T,M,Y,35,KG,20181122,,OT,GB,GB,EFAVIRENZ.,Stevens-Johnson syndrome,150176652,OT,,,150176652,1,20110819,20110920,,,150176652,1,HIV infection
15222669,152226692,2,F,,20181029,20180731,20181112,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-071122,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20181112,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy;Product use issue,152226692,OT,,,,,,,,,152226692,1,Product used for unknown indication
15222670,152226702,2,F,,20181029,20180731,20181112,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-067824,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20181112,,OT,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,152226702,CA,,,,,,,,,152226702,1,Product used for unknown indication
15230085,152300852,2,F,,20180725,20180802,20181220,EXP,,IN-CIPLA LTD.-2018IN20418,CIPLA,"SEHGAL VN, VERMA P, SHARMA S. HIV/AIDS KAPOSI SARCOMA: THE INDIAN PERSPECTIVE. SKINMED. 2013;11 (6):375 TO 377",,,,,Y,,,20181220,,OT,IN,IN,EFAVIRENZ.,Drug ineffective;Pulmonary tuberculosis,152300852,OT,,,,,,,,,152300852,1,Antiretroviral therapy
15235019,152350193,3,F,2006,20181106,20180803,20181109,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-002637",BOEHRINGER INGELHEIM,,,,N,F,Y,1.19,KG,20181109,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal malformation;Spina bifida,152350193,DE,,,152350193,1,20050620,20060216,,,152350193,1,Product used for unknown indication
15239551,152395511,1,I,20100210,20180720,20180803,20180803,EXP,,PT-MYLANLABS-2018M1057421,MYLAN,,27,YR,,M,Y,91,KG,20180802,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;No adverse event,152395511,OT,,,152395511,1,20100210,20100818,,,152395511,1,HIV infection
15245701,152457011,1,I,,20180726,20180806,20180806,EXP,,PHHY2018ES060193,SANDOZ,"BRAVO I, ALVAREZ H, MARINO A, CLOTET B, MOLTO J. RECURRENT CORONARY DISEASE IN HIV-INFECTED PATIENTS: ROLE OF DRUG?DRUG INTERACTIONS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2018;84:1617-9",39,YR,,M,Y,,,20180806,,OT,ES,ES,EFAVIRENZ+ EMTRICITABINE+ TENOFOVIR DISOPROXIL FUMARATE,Acute coronary syndrome;Chest pain;Device related thrombosis;Drug interaction,152457011,HO,,,,,,,,,152457011,1,Product used for unknown indication
15248149,152481495,5,F,20060216,20181009,20180807,20181016,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-002639",BOEHRINGER INGELHEIM,,25,YR,,F,Y,56,KG,20181016,,OT,FR,FR,SUSTIVA,Abortion induced;Insomnia;Pregnancy;Vertigo,152481495,OT,,,152481495,1,20050620,20050908,,,152481495,1,HIV infection
15275860,152758601,1,I,,20180731,20180814,20180814,PER,,US-MYLANLABS-2018M1059845,MYLAN,,,,,M,Y,,,20180814,,CN,US,US,EFAVIRENZ TABLETS USP,Drug ineffective;Lip pain,,,,,,,,,,,152758601,1,Product used for unknown indication
15287323,152873233,3,F,,20181018,20180817,20181101,EXP,,PT-AUROBINDO-AUR-APL-2018-041849,AUROBINDO,,54,YR,,M,Y,,,20181101,,OT,PT,PT,EFAVIRENZ.,Hepatitis B reactivation;Neuropsychiatric symptoms,152873233,OT,,,152873233,1,2014,,,,152873233,1,Antiretroviral therapy
15296511,152965111,1,I,,20180808,20180820,20180820,EXP,,US-MYLANLABS-2018M1061714,MYLAN,"SHAIKH B, SOHAIB M, ALSHANTTI R, BARRERA F, MURVELASHVILI N. A FAST END TO A SLOW DISEASE. J-CLIN-TRANSL-ENDOCRINOL-CASE-REP 2018;9:9-11.",50,YR,,M,Y,,,20180820,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bradycardia;Cardiac arrest;Electrocardiogram QT prolonged;Ventricular arrhythmia,152965111,DE,,,,,,,,,152965111,1,HIV infection
15297051,152970513,3,F,2018,20180913,20180820,20180927,EXP,,UG-MYLANLABS-2018M1062243,MYLAN,,0,YR,,M,Y,2.6,KG,20180927,,CN,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Congenital umbilical hernia;Foetal exposure during pregnancy;Sepsis neonatal;Talipes,152970513,OT,,,152970513,1,20180521,,,,152970513,1,Product used for unknown indication
15302247,153022476,6,F,2014,20181213,20180821,20181220,EXP,,ES-PFIZER INC-2018330979,PFIZER,"BRAVO, I.. RECURRENT CORONARY DISEASE IN HIV-INFECTED PATIENTS: ROLE OF DRUG-DRUG INTERACTIONS.. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2018;84 (7):1617-1619",39,YR,,M,Y,,,20181220,,MD,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Drug interaction;Vascular stent thrombosis,153022476,HO,,,153022476,1,2014,,,,153022476,3,Antiplatelet therapy
15308899,153088992,2,F,2014,20180821,20180823,20180904,EXP,,ES-MACLEODS PHARMACEUTICALS US LTD-MAC2018015707,MACLEODS,,,,,,Y,,,20180904,,CN,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,153088992,OT,,,153088992,1,2012,,,,153088992,1,HIV infection
15357253,153572532,2,F,20060216,20181023,20180906,20181026,EXP,,FR-ABBVIE-18S-056-2474150-00,ABBVIE,,25,YR,,F,Y,,,20181026,,OT,FR,FR,SUSTIVA,Abortion induced;Exposure during pregnancy;Insomnia;Vertigo,153572532,HO,,,153572532,1,20050908,20050908,,,153572532,1,HIV infection
15366222,153662222,2,F,,20181030,20180910,20181106,EXP,FR-EMA-20130214-MMEVHUMANWT-150034270,FR-ABBVIE-18S-056-2473844-00,ABBVIE,,19,YR,,F,Y,,,20181106,,MD,COUNTRY NOT SPECIFIED,FR,SUSTIVA,Drug interaction;Exposure during pregnancy;Normal newborn;Pregnancy on contraceptive,153662222,OT,,,153662222,2,20080727,,,,153662222,1,Product used for unknown indication
15367987,153679874,4,F,20180630,20181018,20180910,20181023,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK156040,VIIV,,39,YR,,F,Y,49,KG,20181023,,MD,CN,CN,EFAVIRENZ.,Hypersensitivity;Liver injury,153679874,HO,,,153679874,1,20180621,20180712,,,153679874,1,HIV infection
15372370,153723702,2,F,20090930,20181106,20180911,20181113,EXP,FR-EMA-20130214-MMEVHUMANWT-150034270,FR-GILEAD-2018-0362320,GILEAD,,19,YR,A,F,Y,,,20181113,,CN,FR,FR,SUSTIVA,Caesarean section;Drug ineffective;Drug interaction;Maternal exposure during pregnancy;Normal newborn;Pregnancy on contraceptive;Unintended pregnancy,153723702,OT,,,153723702,1,20080727,,,,153723702,1,Product used for unknown indication
15386725,153867252,2,F,2014,20181213,20180914,20181221,EXP,,PHHY2018ES049784,SANDOZ,,39,YR,,M,Y,,,20181221,,OT,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,153867252,HO,,,,,,,,,153867252,1,HIV infection
15388183,153881833,3,F,,20180929,20180915,20181012,EXP,,DE-AUROBINDO-AUR-APL-2018-045629,AUROBINDO,"HEZODE C, LEBRAY P, DE LEDINGHEN V, ZOULIM F, DI MARTINO V, BOYER N, ET AL... DACLATASVIR PLUS SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN, FOR HEPATITIS C VIRUS GENOTVPE 3 IN A FRENCH EARLY ACCESS PROGRAMME. LIVER INTEMATIONAL. 2017",,,A,,Y,,,20181012,,,COUNTRY NOT SPECIFIED,DE,EFAVIRENZ.,Abdominal pain;Acute kidney injury;Anaemia;Anal cancer;Arthralgia;Blood creatinine increased;Calculus urinary;Circulatory collapse;Clostridium difficile colitis;Death;Dehydration;Dermatitis allergic;Diarrhoea;Drug withdrawal syndrome;Dyspnoea;Erysipelas;Fatigue;Fluid overload;Gastrointestinal disorder;Gastrointestinal infection;General physical health deterioration;Haemorrhoidal haemorrhage;Headache;Hepatic encephalopathy;Hepatic failure;Hepatitis C;Hepatobiliary disease;Hepatocellular carcinoma;Hypersensitivity vasculitis;Hypertension;Hyponatraemia;Infection;Lactic acidosis;Liver disorder;Lymphoedema;Mental disorder;Myocardial infarction;Nausea;Neoplasm;Neutropenia;Pancreatitis acute;Pancytopenia;Peritonitis;Peritonitis bacterial;Portal vein thrombosis;Sleep disorder;Soft tissue infection;Somnolence;Streptococcal sepsis;Treatment failure;Vertigo,153881833,OT,,,,,,,,,153881833,1,Chronic hepatitis C
15419151,154191513,3,F,,20181124,20180924,20181205,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-078228,BRISTOL MYERS SQUIBB,,27,YR,,,Y,,,20181205,,OT,RO,RO,EFAVIRENZ.,Drug resistance;Meningitis tuberculous,154191513,OT,,,,,,,,,154191513,1,Pulmonary tuberculosis
15431020,154310203,3,F,,20181004,20180926,20181009,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2018172080,VIIV,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A.SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY.2018;1-8. DOI: 10.1159/000490056.",32,YR,,M,Y,,,20181009,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154310203,LT,,,,,,,,,154310203,1,Hepatitis C
15431021,154310213,3,F,,20181004,20180926,20181009,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2018172075,VIIV,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A.SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY.2018;1-8. DOI: 10.1159/000490056.",32,YR,,M,Y,,,20181009,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154310213,OT,,,,,,,,,154310213,1,Hepatitis C
15431111,154311113,3,F,,20181004,20180926,20181009,EXP,,PT-GLAXOSMITHKLINE-PT2018172080,GLAXOSMITHKLINE,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A.SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY.2018;1-8. DOI: 10.1159/000490056.",32,YR,,M,Y,,,20181009,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154311113,LT,,,,,,,,,154311113,1,Hepatitis C
15431112,154311123,3,F,,20181004,20180926,20181009,EXP,,PT-GLAXOSMITHKLINE-PT2018172075,GLAXOSMITHKLINE,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A.SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY.2018;1-8. DOI: 10.1159/000490056.",32,YR,,M,Y,,,20181009,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154311123,OT,,,,,,,,,154311123,1,Hepatitis C
15432248,154322481,1,I,20180905,20180921,20180926,20180926,EXP,,ES-GILEAD-2018-0364767,GILEAD,,22,YR,A,M,Y,,,20180926,,PH,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL TEVA,Infertility,154322481,OT,,,154322481,1,201002,201805,,,154322481,1,Prophylaxis
15432480,154324802,2,F,,20181210,20180927,20181223,EXP,,RO-AUROBINDO-AUR-APL-2018-044439,AUROBINDO,,27,YR,,,Y,,,20181224,,OT,RO,RO,EFAVIRENZ.,Drug resistance;Meningitis tuberculous,154324802,OT,,,,,,,,,154324802,1,Pulmonary tuberculosis
15435619,154356192,2,F,20150708,20181005,20180927,20181009,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-047172,BRISTOL MYERS SQUIBB,,35,YR,,M,Y,59.1,KG,20181009,,CN,US,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Neutropenia;Pneumonia bacterial,154356192,DE,,,154356192,1,20150324,20160201,,,154356192,1,Kaposi's sarcoma AIDS related
15435632,154356322,2,F,,20181023,20180927,20181025,EXP,,PHHY2018PT105702,SANDOZ,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY. 2018;1-8",32,YR,,M,Y,,,20181025,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154356322,OT,,,,,,,,,154356322,1,HIV infection
15438733,154387332,2,F,,20181006,20180928,20181019,EXP,,UG-AUROBINDO-AUR-APL-2018-048507,AUROBINDO,,36,WK,,,Y,2.2,KG,20181019,,MD,UG,UG,EFAVIRENZ.,Ankyloglossia congenital;Foetal exposure during pregnancy,154387332,CA,,,154387332,1,20171030,,,,154387332,1,HIV infection
15439574,154395742,2,F,20171030,20181009,20180928,20181012,EXP,,UG-STRIDES ARCOLAB LIMITED-2018SP008416,STRIDES,,,,N,,Y,2.2,KG,20181012,,OT,BR,BR,EFAVIRENZ.,Ankyloglossia congenital;Foetal exposure during pregnancy;Low birth weight baby;Premature baby,154395742,OT,,,,,,,,,154395742,1,Product used for unknown indication
15439575,154395752,2,F,20171030,20181009,20180928,20181012,EXP,,UG-STRIDES ARCOLAB LIMITED-2018SP008415,STRIDES,,,,,F,Y,,,20181012,,OT,UG,BR,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,154395752,OT,,,154395752,1,20171030,20180302,,,154395752,1,HIV infection
15441050,154410502,2,F,20180907,20181001,20180928,20181012,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088186,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20181012,,OT,ZW,ZW,EFAVIRENZ.,Maternal exposure during pregnancy;Product use issue;Stillbirth,154410502,OT,,,154410502,1,20151015,,,,154410502,1,HIV infection
15451550,154515501,1,I,,20180110,20181001,20181001,EXP,,PHHY2017DE198987,SANDOZ,,25,YR,,F,Y,,,20181001,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,154515501,OT,,,,,,,,,154515501,1,Product used for unknown indication
15455176,154551761,1,I,,20180926,20181002,20181002,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2018175000,VIIV,,,,E,M,Y,,,20181002,,CN,GB,GB,EFAVIRENZ.,Death,154551761,OT,,,,,,,,,154551761,1,Product used for unknown indication
15455536,154555361,1,I,,20180926,20181002,20181002,EXP,,GB-GLAXOSMITHKLINE-GB2018175000,GLAXOSMITHKLINE,,,,E,M,Y,,,20181002,,CN,GB,GB,EFAVIRENZ.,Death,154555361,DE,,,,,,,,,154555361,1,Product used for unknown indication
15456648,154566482,2,F,,20181017,20181002,20181023,EXP,,GB-MYLANLABS-2018M1071213,MYLAN,"WAITT C, WALIMBWA S I, ORRELL C, LAMORDE M, HEIBERG C, MEHTA U, ET AL. DOLPHIN-1: DOLUTEGRAVIR VS EFAVIRENZ WHEN INITIATING TREATMENT IN LATE PREGNANCY.. TOP. ANTIVIRAL MED.. 2018;26 (SUPPL 1):360S",,,,F,Y,,,20181023,,OT,GB,GB,EFAVIRENZ.,Hypertension;Liver function test increased;Maternal exposure during breast feeding;Maternal exposure during pregnancy;Product use issue;Stillbirth,154566482,OT,,,,,,,,,154566482,1,HIV infection
15456659,154566591,1,I,,20180924,20181002,20181002,EXP,,GB-MYLANLABS-2018M1071216,MYLAN,"WAITT C, WALIMBWA S I, ORRELL C, LAMORDE M, HEIBERG C, MEHTA U,. DOLPHIN-1: DOLUTEGRAVIR VS EFAVIRENZ WHEN INITIATING TREATMENT IN LATE PREGNANCY.. TOPICS IN ANTIVIRAL MEDICINE.. 2018;26 (SUPPL 1):360S",,,I,,Y,,,20180929,,OT,GB,GB,EFAVIRENZ.,Exposure via breast milk;Foetal exposure during pregnancy;Polydactyly,154566591,OT,,,,,,,,,154566591,1,Product used for unknown indication
15456922,154569221,1,I,,20180925,20181002,20181002,EXP,,IN-MYLANLABS-2018M1072052,MYLAN,"GOYAL A, BISWAS A. SEVERE LIPODYSTROPHY AND GYNECOMASTIA IN A MALE PATIENT ON LOPINAVIR-BASED SECOND-LINE ANTIRETROVIRAL THERAPY. TURK-J-ENDOCRIN-METAB 2018;22(3):208-212.",,,A,M,Y,100.5,KG,20181002,,OT,IN,IN,EFAVIRENZ.,Acanthosis nigricans;Diabetes mellitus;Dyslipidaemia;Gynaecomastia;Lipodystrophy acquired,154569221,OT,,,154569221,1,2004,200703,,,154569221,1,HIV infection
15457218,154572181,1,I,201808,20180924,20181002,20181002,EXP,,BW-GILEAD-2018-0365714,GILEAD,,41,YR,A,M,Y,,,20181002,,MD,BW,BW,EFAVIRENZ.,Meningitis cryptococcal,154572181,OT,,,154572181,1,201807,,,,154572181,1,HIV infection
15458050,154580502,2,F,,20181210,20181003,20181223,EXP,,PT-AUROBINDO-AUR-APL-2018-047800,AUROBINDO,,32,YR,,M,Y,,,20181224,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154580502,OT,,,,,,,,,154580502,1,Chronic hepatitis C
15459284,154592841,1,I,,20180924,20181003,20181003,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-092024,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,,,20181003,,CN,US,US,SUSTIVA,Drug resistance,154592841,OT,,,,,,,,,154592841,1,Product used for unknown indication
15463001,154630011,1,I,2014,20180928,20181004,20181004,PER,,IN-LAURUS LABS LIMITED-201800200,LAURUS LABS LIMITED,,,,A,M,Y,,,20181004,,OT,IN,IN,EFAVIRENZ.,Central obesity;Dyslipidaemia;Gynaecomastia;Lipodystrophy acquired;Lipohypertrophy;Weight increased,154630011,OT,,,154630011,4,200401,200703,,,154630011,1,HIV infection
15463641,154636411,1,I,,20180919,20181004,20181004,EXP,,PT-AUROBINDO-AUR-APL-2018-048162,AUROBINDO,,29,YR,,M,Y,,,20181004,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154636411,OT,,,,,,,,,154636411,1,Hepatitis C
15464081,154640812,2,F,,20181008,20181004,20181023,EXP,,UG-MYLANLABS-2018M1072109,MYLAN,,,,I,,Y,,,20181023,,OT,UG,BR,EFAVIRENZ.,Ankyloglossia congenital;Foetal exposure during pregnancy,154640812,OT,,,154640812,1,20171030,,,,154640812,1,Product used for unknown indication
15466091,1546609110,10,F,,20181217,20181004,20181221,EXP,,PT-PFIZER INC-2018394465,PFIZER,"SOARES, J.. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY. 2018;61 (2):64-71",32,YR,,M,Y,,,20181221,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,1546609110,LT,,,,,,,,,1546609110,2,HIV infection
15467352,154673521,1,I,,20180924,20181005,20181005,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-089016,BRISTOL MYERS SQUIBB,,,,E,M,Y,,,20181005,,CN,GB,GB,EFAVIRENZ.,Death,154673521,OT,,,,,,,,,154673521,1,Product used for unknown indication
15473306,154733063,3,F,,20181128,20181008,20181210,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-089598,BRISTOL MYERS SQUIBB,,32,YR,,M,Y,,,20181210,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154733063,LT,,,,,,,,,154733063,1,Chronic hepatitis C
15474715,154747153,3,F,,20181211,20181008,20181223,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-090174,BRISTOL MYERS SQUIBB,,32,YR,,M,Y,,,20181223,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154747153,OT,,,,,,,,,154747153,1,Chronic hepatitis C
15474937,154749371,1,I,,20181001,20181008,20181008,EXP,,US-TEVA-2018-US-961730,TEVA,"DURHAM SH, COVINGTON EW, CLEMMONS KJ. HEPATOTOXICITY UPON USING NIACIN TO PASS A DRUG TEST: A CASE REPORT. J-AM-PHARMACISTS-ASSOC 2018;58(5):564-567.",,,A,M,Y,,,20181008,,PH,US,US,Efavirenz/emtricitabine/tenofovir desoproxil,Hepatotoxicity;Intentional product misuse,154749371,OT,,,,,,,,,154749371,2,HIV infection
15475994,154759941,1,I,20180712,20181003,20181009,20181009,EXP,,PHHY2018FR119348,SANDOZ,,65,YR,,F,Y,,,20181009,,OT,COUNTRY NOT SPECIFIED,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Lactic acidosis;Metabolic acidosis;Renal failure;Septic shock;Urinary tract infection,154759941,HO,,,,,,,,,154759941,1,Diabetes mellitus
15476035,154760352,2,F,,20181020,20181009,20181102,EXP,,FR-AUROBINDO-AUR-APL-2018-010078,AUROBINDO,,54,YR,,M,Y,,,20181102,,OT,FR,FR,EFAVIRENZ.,Haematotoxicity,154760352,OT,,,154760352,1,200709,200804,,,154760352,1,Chronic hepatitis C
15476618,154766183,3,F,,20181210,20181009,20181224,EXP,,PT-AUROBINDO-AUR-APL-2018-048824,AUROBINDO,,32,YR,,M,Y,,,20181224,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154766183,LT,,,,,,,,,154766183,1,Hepatitis C
15480033,154800332,2,F,,20181214,20181009,20181219,EXP,,PT-GILEAD-2018-0367224,GILEAD,SOARES J. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY. 2018;UNK:1-8. DOI:10.1159/000490056,29,YR,A,M,Y,,,20181219,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,154800332,OT,,,,,,,,,154800332,1,Chronic hepatitis C
15480679,154806792,2,F,,20181023,20181010,20181101,EXP,,PHHY2009FR075290,SANDOZ,,25,YR,,F,Y,,,20181101,,OT,FR,FR,EFAVIRENZ.,Exposure during pregnancy;Insomnia;Vertigo,154806792,OT,,,154806792,1,20050620,20050908,,,154806792,1,HIV infection
15481222,154812221,1,I,,20181005,20181010,20181010,EXP,,KE-HETERO CORPORATE-HET2018KE01038,HETERO,,,,,F,Y,,,20181010,,PH,KE,KE,Efavirenz+Lamivudine+Tenofovir,Abortion threatened;Dizziness;Hallucination;Headache;Nightmare;Pruritus generalised;Rash;Somnolence,154812221,OT,,,,,,,,,154812221,1,Product used for unknown indication
15488800,154888002,2,F,,20180926,20181011,20181015,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-095224,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181015,,MD,AT,AT,EFAVIRENZ.,Foetal exposure during pregnancy;Plagiocephaly,154888002,OT,,,,,,,,,154888002,1,Product used for unknown indication
15488801,154888012,2,F,,20180926,20181011,20181015,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-090269,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,,,20181015,,MD,AT,AT,EFAVIRENZ.,Acute stress disorder;Live birth;Maternal exposure during pregnancy;Premature rupture of membranes;Product use issue,154888012,OT,,,,,,,,,154888012,1,Antiretroviral therapy
15493462,154934622,2,F,20150708,20181012,20181012,20181031,EXP,,MW-GILEAD-2015-0163489,GILEAD,,35,YR,A,M,Y,60.4,KG,20181031,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aspartate aminotransferase increased;Kaposi's sarcoma;Pneumonia bacterial,154934622,OT,,,154934622,1,20150324,20150324,,,154934622,1,Kaposi's sarcoma AIDS related
15497669,154976691,1,I,20180712,20181002,20181015,20181015,EXP,FR-AFSSAPS-PC20180811,FR-BAUSCH-BL-2018-027379,BAUSCH AND LOMB,,65,YR,,F,Y,,,20181015,,PH,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL BIOGARAN,Lactic acidosis;Metabolic acidosis;Renal failure;Septic shock;Urinary tract infection,154976691,HO,,,154976691,1,20180414,20180713,,,154976691,1,Diabetes mellitus
15498174,154981741,1,I,20180712,20180930,20181015,20181015,EXP,,FR-AUROBINDO-AUR-APL-2018-050299,AUROBINDO,,65,YR,,F,Y,,,20181015,,PH,FR,FR,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Lactic acidosis;Metabolic acidosis;Renal failure;Septic shock;Urinary tract infection,154981741,HO,,,154981741,2,20180414,,,,154981741,1,Diabetes mellitus
15507656,155076561,1,I,,20181010,20181016,20181016,EXP,,US-GILEAD-2018-0368492,GILEAD,,56,YR,A,F,Y,,,20181016,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,CD4 lymphocytes decreased;Drug ineffective;Viral load increased,155076561,OT,,,,,,,,,155076561,1,HIV infection
15510768,155107681,1,I,,20181008,20181016,20181016,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018186257,VIIV,"CORBIN V, FRANGE P, VEBER F, BLANCHE S, RUNEL-BELLIARD C, LALANDE M, ET AL. CLINICAL, VIROLOGICAL AND IMMUNOLOGICAL FEATURES OF HIV-POSITIVE CHILDREN INTERNATIONALLY ADOPTED IN FRANCE FROM 2005-2015. PLOS ONE. 2018;13(9):E0203438. DOI: 10.1371/JOURNAL.PONE.0203438.",3,YR,,,Y,,,20181016,,OT,FR,FR,EFAVIRENZ.,Virologic failure,155107681,OT,,,,,,,,,155107681,1,HIV infection
15510776,155107761,1,I,,20181008,20181016,20181016,EXP,,FR-GLAXOSMITHKLINE-FR2018186257,GLAXOSMITHKLINE,"CORBIN V, FRANGE P, VEBER F, BLANCHE S, RUNEL-BELLIARD C, LALANDE M, ET AL. CLINICAL, VIROLOGICAL AND IMMUNOLOGICAL FEATURES OF HIV-POSITIVE CHILDREN INTERNATIONALLY ADOPTED IN FRANCE FROM 2005-2015. PLOS ONE. 2018;13(9):E0203438. DOI: 10.1371/JOURNAL.PONE.0203438.",3,YR,,,Y,,,20181016,,OT,FR,FR,EFAVIRENZ.,Virologic failure,155107761,OT,,,,,,,,,155107761,1,HIV infection
15515252,155152522,2,F,,20181019,20181017,20181031,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-078173,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20181031,,OT,PT,PT,EFAVIRENZ.,Neuropsychiatric symptoms,155152522,OT,,,,,,,,,155152522,1,Chronic hepatitis C
15517352,155173521,1,I,,20181005,20181017,20181017,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-093898,BRISTOL MYERS SQUIBB,,96,YR,,M,Y,,,20181017,,PH,CA,CA,SUSTIVA,Dementia;Dysphagia,155173521,OT,,,,,,,,,155173521,1,HIV infection
15524974,155249741,1,I,,20181009,20181018,20181018,EXP,,BR-HETERO CORPORATE-HET2018BR01048,HETERO,,,,,,Y,2.2,KG,20181018,,OT,BR,BR,EFAVIRENZ.,Ankyloglossia congenital;Foetal exposure during pregnancy;Low birth weight baby;Premature baby,155249741,OT,,,155249741,1,20171030,20180302,,,155249741,1,HIV infection
15525391,155253911,1,I,,20181008,20181018,20181018,EXP,,PH-GLAXOSMITHKLINE-PH2018188199,GLAXOSMITHKLINE,"FRANCISCO CN., ALEJANDRIA M, SALVANA E.M, DE VERA ANDAL VM.. PRIMARY INTRACRANIAL LEIOMYOSARCOMA AMONG PATIENTS WITH AIDS IN THE ERA OF NEW CHEMOTHERAPEUTIC AND BIOLOGICAL AGENTS.. BMJ CASE REPORTS. 2018 (NO PAGINATION), 2018. ARTICLE NUMBER: BCR-2018-225714. D. 2018;UNK:1-6",36,YR,,M,Y,,,20181018,,MD,PH,PH,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,155253911,OT,,,,,,,,,155253911,1,HIV infection
15525501,155255011,1,I,,20181008,20181018,20181018,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2018188199,VIIV,"FRANCISCO CN., ALEJANDRIA M, SALVANA E.M, DE VERA ANDAL VM.. PRIMARY INTRACRANIAL LEIOMYOSARCOMA AMONG PATIENTS WITH AIDS IN THE ERA OF NEW CHEMOTHERAPEUTIC AND BIOLOGICAL AGENTS.. BMJ CASE REPORTS. 2018 (NO PAGINATION), 2018. ARTICLE NUMBER: BCR-2018-225714. D. 2018;UNK:1-6",36,YR,,M,Y,,,20181018,,MD,PH,PH,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,155255011,OT,,,,,,,,,155255011,1,HIV infection
15525745,155257451,1,I,201807,20181015,20181019,20181019,EXP,,PHHY2018LS131116,NOVARTIS,,47,YR,,F,Y,,,20181019,,MD,LS,LS,EFAVIRENZ.,Acute kidney injury;Anaemia;Deep vein thrombosis;Metabolic acidosis;Pancreatic carcinoma;Pulmonary embolism;Respiratory failure;Weight decreased,155257451,DE,,,155257451,2,20180702,20180912,,,155257451,1,Tuberculosis
15527156,155271562,2,F,20181001,20181027,20181020,20181105,EXP,,ZA-AUROBINDO-AUR-APL-2018-051204,AUROBINDO,,43,YR,,F,Y,,,20181105,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Abortion induced;Exposure during pregnancy;Foetal death,155271562,OT,,,155271562,1,20140101,,,,155271562,1,HIV infection
15530457,155304571,1,I,20180120,20181010,20181018,20181018,EXP,FR-AFSSAPS-TO20184140,FR-PFIZER INC-2018413828,PFIZER,,61,YR,,F,Y,,,20181018,,MD,FR,FR,SUSTIVA,Acute kidney injury;Renal tubular disorder,155304571,HO,,,155304571,1,20180117,20180214,,,155304571,1,Pelvic infection
15530658,155306581,1,I,,20181012,20181018,20181018,EXP,,US-GILEAD-2018-0369027,GILEAD,,49,YR,A,M,Y,,,20181018,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood HIV RNA increased;Product use issue,155306581,OT,,,155306581,1,2007,,,,155306581,1,HIV infection
15530756,155307562,2,F,20151021,20181018,20181018,20181025,EXP,,MW-GILEAD-2018-0368297,GILEAD,,31,YR,A,M,Y,,,20181025,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis,155307562,OT,,,155307562,1,20150527,20151020,,,155307562,1,Kaposi's sarcoma AIDS related
15535398,155353981,1,I,20180303,20181009,20181022,20181022,EXP,,BR-HETERO CORPORATE-HET2018BR01049,HETERO,,,,,F,Y,,,20181022,,OT,BR,BR,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,155353981,OT,,,155353981,1,20171030,20180302,,,155353981,1,HIV infection
15535544,155355441,1,I,,20171206,20181022,20181022,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-BI-065458",BOEHRINGER INGELHEIM,"MULU A, MAIER M, LIEBERT UG. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: A DECADE LONGITUDINAL STUDY. PLOS ONE. 2017;12 (10)",43,YR,,F,Y,,,20181022,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Viral mutation identified,155355441,OT,,,,,,,,,155355441,1,Product used for unknown indication
15542106,155421061,1,I,,20181009,20181023,20181023,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018017499,MACLEODS,,,,,,Y,,,20181023,,OT,US,US,EFAVIRENZ.,Congenital tongue anomaly;Foetal exposure during pregnancy,155421061,CA,,,155421061,1,20171030,20180302,,,155421061,1,HIV infection
15544242,155442421,1,I,20180712,20181022,20181024,20181024,EXP,FR-AFSSAPS-PC20180811,FR-TEVA-2018-FR-967782,TEVA,,65,YR,,F,Y,,,20181024,,PH,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL BIOGARAN,Lactic acidosis;Metabolic acidosis;Renal failure;Septic shock;Urinary tract infection,155442421,HO,,,155442421,1,20180414,20180713,,,155442421,1,Diabetes mellitus
15548695,155486951,1,I,20180712,20181010,20181025,20181025,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-188898,RANBAXY,,65,YR,,F,Y,,,20181025,,OT,GB,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL BIOGARAN,Lactic acidosis;Metabolic acidosis;Renal failure;Septic shock;Urinary tract infection,155486951,HO,,,155486951,1,20180414,20180713,,,155486951,1,Diabetes mellitus
15549335,155493351,1,I,20180905,20181011,20181025,20181025,EXP,,FR-AUROBINDO-AUR-APL-2018-051803,AUROBINDO,,,,,,Y,,,20181025,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Kidney malformation,155493351,OT,,,155493351,1,20180417,20180706,,,155493351,1,Maternal exposure timing unspecified
15550384,155503841,1,I,,20181012,20181025,20181025,EXP,,US-AUROBINDO-AUR-APL-2018-051482,AUROBINDO,,25,YR,,M,Y,,,20181025,,OT,US,US,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Alanine aminotransferase increased;Aspartate aminotransferase increased;Hepatotoxicity;Intentional product misuse;Liver injury,155503841,OT,,,,,,,,,155503841,1,Product used for unknown indication
15550539,155505391,1,I,,20181016,20181025,20181025,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018193746,VIIV,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",35,YR,,M,Y,,,20181025,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Intracranial pressure increased,155505391,LT,,,,,,,,,155505391,1,Meningitis cryptococcal
15550540,155505402,2,F,,20181016,20181025,20181029,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018193747,VIIV,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",35,YR,,M,Y,,,20181029,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155505402,OT,,,,,,,,,155505402,1,HIV infection
15550541,155505411,1,I,,20181016,20181025,20181025,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018193745,VIIV,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",45,YR,,M,Y,,,20181025,,MD,UG,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155505411,DE,,,,,,,,,155505411,1,Cryptococcal fungaemia
15550544,155505441,1,I,,20181016,20181025,20181025,EXP,,UG-GLAXOSMITHKLINE-UG2018193746,GLAXOSMITHKLINE,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",35,YR,,M,Y,,,20181025,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Intracranial pressure increased,155505441,DE,,,,,,,,,155505441,1,Meningitis cryptococcal
15550548,155505482,2,F,,20181016,20181025,20181029,EXP,,UG-GLAXOSMITHKLINE-UG2018193747,GLAXOSMITHKLINE,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",35,YR,,M,Y,,,20181029,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155505482,HO,,,,,,,,,155505482,1,HIV infection
15550553,155505531,1,I,,20181016,20181025,20181025,EXP,,UG-GLAXOSMITHKLINE-UG2018193745,GLAXOSMITHKLINE,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",45,YR,,M,Y,,,20181025,,MD,UG,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155505531,OT,,,,,,,,,155505531,1,Cryptococcal fungaemia
15555409,155554091,1,I,20181019,,20181022,20181022,DIR,,,FDA-CTU,,46,YR,,M,N,,,20181019,N,PH,US,US,SUSTIVA,Blood cholesterol increased,,,155554091,HP,155554091,1,2017,,,,,,
15555421,155554212,2,F,,20181025,20181026,20181031,EXP,,UG-PFIZER INC-2018438098,PFIZER,"ABASSI, M.. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2018;5 (1):10.1093/OFID/OFX274",35,YR,,M,Y,,,20181031,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Intracranial pressure increased,155554212,HO,,,,,,,,,155554212,1,Meningitis cryptococcal
15555706,155557062,2,F,,20181025,20181026,20181031,EXP,,UG-PFIZER INC-2018438235,PFIZER,"ABASSI, M.. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2018;5(1):10.1093/OFID/OFX274",35,YR,,M,Y,,,20181031,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration,155557062,DE,,,,,,,,,155557062,1,Meningitis cryptococcal
15556297,155562974,4,F,,20181206,20181026,20181214,EXP,,UG-PFIZER INC-2018438276,PFIZER,"ABASSI, M.. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2018;5 (1):10.1093/OFID/OFX274",45,YR,,M,Y,,,20181214,,MD,UG,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155562974,OT,,,,,,,,,155562974,1,Cryptococcal fungaemia
15558215,155582151,1,I,,20181009,20181027,20181027,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-094803,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20181027,,CN,US,US,SUSTIVA,Pyrexia;Rash,,,,,,,,,,,155582151,1,Product used for unknown indication
15559268,155592681,1,I,20180917,20181001,20181029,20181029,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-098134,BRISTOL MYERS SQUIBB,,47,YR,,F,Y,47,KG,20181029,,OT,US,US,EFAVIRENZ.,Anaemia;International normalised ratio increased;Metabolic acidosis;Pancreatic carcinoma;Pulmonary embolism;Respiratory failure;Weight decreased,155592681,DE,,,155592681,4,20180727,20180912,,,155592681,1,Deep vein thrombosis
15559787,155597873,3,F,,20181210,20181029,20181219,EXP,,PHHY2018PT113969,SANDOZ,,32,YR,,M,Y,,,20181219,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,155597873,OT,,,,,,,,,155597873,1,HIV infection
15565558,155655581,1,I,,20181016,20181030,20181030,EXP,,FR-AUROBINDO-AUR-APL-2018-052499,AUROBINDO,,3,YR,,,Y,,,20181030,,OT,FR,FR,EFAVIRENZ.,Virologic failure,155655581,OT,,,,,,,,,155655581,1,HIV infection
15567325,155673251,1,I,,20181022,20181030,20181030,EXP,,UG-GILEAD-2018-0370962,GILEAD,"MAHSA ABASSI, JOSHUA RHEIN, DAVID B MEYA,  DAVID R BOULWARE. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. FORUM INFECTIOUS DISEASES. 2018;UNK:UNK. DOI:10.1093/OFID/OFX274",35,YR,A,M,Y,,,20181030,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,155673251,DE,,,,,,,,,155673251,1,HIV test positive
15567332,155673321,1,I,,20181022,20181030,20181030,EXP,,UG-GILEAD-2018-0370961,GILEAD,"MAHSA ABASSI, JOSHUA RHEIN, DAVID B MEYA,  DAVID R BOULWARE. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. FORUM INFECTIOUS DISEASES. 2018;UNK:UNK. DOI:10.1093/OFID/OFX274",35,YR,A,M,Y,,,20181030,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,155673321,DE,,,,,,,,,155673321,1,HIV test positive
15567504,155675041,1,I,,20181022,20181030,20181030,EXP,,UG-GILEAD-2018-0370960,GILEAD,"ABASSI M, RHEIN J, MEYA D B, BOULWARE D R. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. FORUM INFECTIOUS DISEASES. 2018;5:1. DOI:DOI.ORG/10.1093/OFID/OFX274",45,YR,A,M,Y,,,20181030,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,155675041,DE,,,,,,,,,155675041,1,HIV infection
15569050,155690501,1,I,,20181023,20181031,20181031,EXP,UG-MLMSERVICE-20181017-1429060-2,UG-CIPLA LTD.-2018UG22190,CIPLA,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR.. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2017;1 TO 4",,,,,Y,,,20181031,,OT,UG,UG,EFAVIRENZ.,Meningitis cryptococcal,155690501,DE,,,,,,,,,155690501,1,HIV infection
15573380,155733801,1,I,,20181023,20181101,20181101,EXP,UG-MLMSERVICE-20181017-1429060-1,UG-CIPLA LTD.-2018UG22189,CIPLA,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR.. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2017;1 TO 4",,,,,Y,,,20181101,,OT,UG,UG,EFAVIRENZ.,Meningitis cryptococcal,155733801,DE,,,,,,,,,155733801,1,HIV infection
15573949,155739492,2,F,,20181022,20181101,20181224,EXP,,IN-CIPLA LTD.-2018IN22202,CIPLA,"RAMRAKHIANI N, MISHRA V. NEUROLOGIC IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A SEROPOSITIVE PATIENT: AN INTERESTING CASE. NEUROLOGY INDIA. 2016;64 (1):155 TO 157",,,,,Y,,,20181224,,OT,IN,IN,EFAVIRENZ.,Anal incontinence;Condition aggravated;Depressed level of consciousness;Immune reconstitution inflammatory syndrome;Urinary incontinence,155739492,OT,,,155739492,1,201309,201311,,,155739492,1,HIV infection
15575661,155756611,1,I,,20181026,20181101,20181101,EXP,,IT-MYLANLABS-2018M1081591,MYLAN,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL.. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITAL. J. PEDIATR.. 2018;44(37)",17,YR,,F,Y,,,20181031,,OT,IT,NG,EFAVIRENZ.,Drug resistance;Viral mutation identified,155756611,OT,,,,,,,,,155756611,1,HIV infection
15575720,155757201,1,I,,20181026,20181101,20181101,EXP,,IT-MYLANLABS-2018M1081600,MYLAN,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G,. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITAL. J. PEDIATR.. 2018;44(37)",16,YR,,M,Y,,,20181101,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,155757201,OT,,,,,,,,,155757201,1,HIV infection
15575733,155757331,1,I,,20181026,20181101,20181101,EXP,,IT-MYLANLABS-2018M1081593,MYLAN,"BRUZZESE E, VECCHIO AL, SMARRAZZO A, TAMBARO O, PALMIERO G, BONADIES G, ET AL.. DOLUTEGRAVIR-BASED ANTI-RETROVIRAL THERAPY IS EFFECTIVE AND SAFE IN HIV-INFECTED PAEDIATRIC PATIENTS.. ITAL. J. PEDIATR.. 2018;44(37)",18,YR,,F,Y,,,20181031,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,155757331,OT,,,,,,,,,155757331,1,HIV infection
15576131,155761311,1,I,,20181026,20181101,20181101,EXP,,FR-MYLANLABS-2018M1081787,MYLAN,,43,YR,,F,Y,,,20181101,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,155761311,OT,,,,,,,,,155761311,1,HIV infection
15577080,155770801,1,I,,20181023,20181101,20181101,EXP,,UG-BAXTER-2018BAX026580,BAXTER,"ABASSI M, RHEIN J, MEYA D, BOULWARE D. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2018;5(1):.",35,YR,,M,Y,,,20181101,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Intracranial pressure increased,155770801,OT,,,,,,,,,155770801,1,Meningitis cryptococcal
15577090,155770901,1,I,,20181023,20181101,20181101,EXP,,UG-BAXTER-2018BAX026587,BAXTER,"ABASSI M, RHEIN J, MEYA D, BOULWARE D. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2018;5(1):.",45,YR,,M,Y,,,20181101,,MD,UG,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155770901,OT,,,,,,,,,155770901,1,Cryptococcal fungaemia
15577093,155770931,1,I,,20181023,20181101,20181101,EXP,,UG-BAXTER-2018BAX026581,BAXTER,"ABASSI M, RHEIN J, MEYA D, BOULWARE D. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2018;5(1):.",35,YR,,M,Y,,,20181101,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155770931,OT,,,,,,,,,155770931,1,Meningitis cryptococcal
15578283,155782831,1,I,,20181023,20181102,20181102,EXP,,UG-CIPLA LTD.-2018UG22174,CIPLA,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR.. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2017;1 TO 4",,,,,Y,,,20181102,,OT,UG,UG,EFAVIRENZ.,Meningitis cryptococcal,155782831,DE,,,,,,,,,155782831,1,HIV infection
15578545,155785451,1,I,,20181023,20181102,20181102,EXP,,UG-ZYDUS-029399,ZYDUS PHARM,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF TEST AND TREAT: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",45,YR,,M,Y,,,20181102,,MD,UG,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155785451,DE,,,,,,,,,155785451,1,Cryptococcal fungaemia
15578546,155785461,1,I,,20181023,20181102,20181102,EXP,,UG-ZYDUS-029415,ZYDUS PHARM,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF TEST AND TREAT: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",35,YR,,M,Y,,,20181102,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Intracranial pressure increased,155785461,LT,,,,,,,,,155785461,1,HIV infection
15578554,155785541,1,I,,20181023,20181102,20181102,EXP,,UG-ZYDUS-029502,ZYDUS PHARM,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF TEST AND TREAT: IS THERE CAUSE FOR CONCERN? OPEN FORUM INFECTIOUS DISEASES. 2018;5(1). DOI:10.1093/OFID/OFX274",35,YR,,M,Y,,,20181102,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155785541,HO,,,,,,,,,155785541,1,HIV infection
15580903,155809031,1,I,,20181023,20181105,20181105,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-100299,BRISTOL MYERS SQUIBB,,45,YR,,M,Y,,,20181105,,OT,UG,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155809031,DE,,,,,,,,,155809031,1,HIV infection
15580993,155809931,1,I,,20181023,20181105,20181105,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-100312,BRISTOL MYERS SQUIBB,,35,YR,,M,Y,,,20181105,,OT,UG,UG,EFAVIRENZ.,General physical health deterioration;Intracranial pressure increased,155809931,LT,,,,,,,,,155809931,1,HIV infection
15582640,155826401,1,I,,20181022,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103249,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155826401,OT,,,,,,,,,155826401,1,HIV infection
15582652,155826521,1,I,,20181022,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103247,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155826521,OT,,,,,,,,,155826521,1,HIV infection
15582653,155826531,1,I,,20181022,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-101808,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155826531,OT,,,,,,,,,155826531,1,HIV infection
15582654,155826541,1,I,,20181022,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103248,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155826541,OT,,,,,,,,,155826541,1,HIV infection
15582779,155827791,1,I,,20181022,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103252,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155827791,OT,,,,,,,,,155827791,1,HIV infection
15582780,155827801,1,I,,20181022,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103254,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155827801,OT,,,,,,,,,155827801,1,HIV infection
15582803,155828031,1,I,,20181022,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103251,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155828031,OT,,,,,,,,,155828031,1,HIV infection
15582805,155828051,1,I,,20181022,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103253,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155828051,OT,,,,,,,,,155828051,1,HIV infection
15582808,155828081,1,I,,20181022,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103250,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155828081,OT,,,,,,,,,155828081,1,HIV infection
15582810,155828101,1,I,,20181022,20181105,20181105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103255,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20181105,,OT,ZA,ZA,EFAVIRENZ.,Nephropathy toxic,155828101,OT,,,,,,,,,155828101,1,HIV infection
15583294,155832941,1,I,,20181023,20181103,20181103,EXP,,UG-MACLEODS PHARMACEUTICALS US LTD-MAC2018018452,MACLEODS,,,,,,Y,,,20181103,,CN,IN,UG,EFAVIRENZ.,General physical health deterioration;Intracranial pressure increased,155832941,DE,,,,,,,,,155832941,1,HIV infection
15583302,155833021,1,I,,20181023,20181103,20181103,EXP,,UG-MACLEODS PHARMACEUTICALS US LTD-MAC2018018451,MACLEODS,,,,,,Y,,,20181103,,CN,IN,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155833021,LT,,,,,,,,,155833021,1,HIV infection
15583305,155833051,1,I,,20181023,20181103,20181103,EXP,,UG-MACLEODS PHARMACEUTICALS US LTD-MAC2018018453,MACLEODS,,,,,,Y,,,20181103,,CN,IN,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155833051,HO,,,,,,,,,155833051,1,HIV infection
15583421,155834211,1,I,,20181023,20181105,20181105,EXP,,UG-AUROBINDO-AUR-APL-2018-053001,AUROBINDO,,35,YR,,M,Y,,,20181105,,MD,UG,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155834211,DE,,,,,,,,,155834211,1,HIV infection
15583549,155835492,2,F,,20181105,20181105,20181118,EXP,,UG-AUROBINDO-AUR-APL-2018-053002,AUROBINDO,,35,YR,,M,Y,,,20181118,,MD,UG,UG,EFAVIRENZ.,Confusional state;Cough;General physical health deterioration;Headache;Immune reconstitution inflammatory syndrome;Intracranial pressure increased;Respiratory failure;Unresponsive to stimuli;Vomiting,155835492,OT,,,,,,,,,155835492,1,HIV infection
15585465,155854651,1,I,,20181024,20181105,20181105,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-100913,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20181105,,CN,US,US,SUSTIVA,Pancreatitis,155854651,OT,,,,,,,,,155854651,1,Product used for unknown indication
15585586,155855861,1,I,,20181023,20181104,20181104,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-100462,BRISTOL MYERS SQUIBB,,35,YR,,M,Y,,,20181104,,OT,US,UG,EFAVIRENZ.,General physical health deterioration;Immune reconstitution inflammatory syndrome;Respiratory failure;Sepsis;Unresponsive to stimuli,155855861,LT,,,,,,,,,155855861,1,HIV infection
15585661,155856611,1,I,,20181023,20181105,20181105,EXP,,"TZ-LANNETT COMPANY, INC.-TZ-2018LAN001265",LANNETT,"LUWANDA LB, GAMELL A. ISONIAZID-INDUCED SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS IN AN HIV-POSITIVE WOMAN: A RARE SIDE EFFECT TO BE AWARE OF WITH THE CURRENT EXPANSION OF ISONIAZID PREVENTIVE THERAPY. PAN-AFR-MED-J. 2018;29:200",40,YR,,F,Y,,,20181105,,OT,TZ,TZ,TENOFOVIR + LAMIVUDINE + EFAVIRENZ,Subacute cutaneous lupus erythematosus,155856611,OT,,,,,,,,,155856611,1,Prophylaxis
15586886,155868861,1,I,200507,20181026,20181105,20181105,EXP,,FR-GILEAD-2018-0371637,GILEAD,,42,YR,A,F,Y,,,20181105,,MD,FR,FR,EFAVIRENZ.,Blood HIV RNA increased;Drug ineffective;Therapy cessation,155868861,OT,,,155868861,1,200308,200507,,,155868861,1,HIV infection
15588896,155888961,1,I,,20181023,20181106,20181106,EXP,,UG-AUROBINDO-AUR-APL-2018-053000,AUROBINDO,,45,YR,,M,Y,,,20181106,,MD,UG,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155888961,OT,,,,,,,,,155888961,1,HIV infection
15589909,155899091,1,I,,20181024,20181106,20181106,EXP,,UG-MYLANLABS-2018M1082075,MYLAN,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN? OPEN-FORUM-INFECT-DIS 2018;5(1):NO PAGINATION.",45,YR,,M,Y,,,20181106,,OT,UG,UG,EFAVIRENZ.,Condition aggravated;Cryptococcosis;Generalised tonic-clonic seizure;Hypotension;Hypoxia;Immune reconstitution inflammatory syndrome;Loss of consciousness;Unmasking of previously unidentified disease,155899091,DE,,,,,,,,,155899091,1,HIV infection
15590305,155903051,1,I,,20181029,20181106,20181106,EXP,,FR-MYLANLABS-2018M1082415,MYLAN,,27,YR,,F,Y,,,20181101,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,155903051,OT,,,,,,,,,155903051,1,HIV infection
15590317,155903173,3,F,,20181211,20181106,20181217,EXP,,FR-MYLANLABS-2018M1082403,MYLAN,,34,YR,,M,Y,,,20181217,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment failure;Treatment noncompliance;Vertigo,155903173,OT,,,,,,,,,155903173,1,Product used for unknown indication
15590323,155903231,1,I,,20181029,20181106,20181106,EXP,,FR-MYLANLABS-2018M1082410,MYLAN,,49,YR,,M,Y,,,20181102,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,155903231,OT,,,,,,,,,155903231,1,Product used for unknown indication
15591956,155919561,1,I,,20181029,20181106,20181106,EXP,,GH-GILEAD-2018-0372669,GILEAD,,,,A,,Y,,,20181106,,MD,GB,GH,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,155919561,OT,,,,,,,,,155919561,1,HIV infection
15591972,155919721,1,I,,20181029,20181106,20181106,EXP,,GH-GILEAD-2018-0372670,GILEAD,,,,A,,Y,,,20181106,,MD,GB,GH,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,155919721,OT,,,,,,,,,155919721,1,HIV infection
15591973,155919731,1,I,,20181029,20181106,20181106,EXP,,GH-GILEAD-2018-0372675,GILEAD,,,,A,,Y,,,20181106,,MD,GB,GH,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,155919731,OT,,,,,,,,,155919731,1,HIV infection
15592041,155920411,1,I,,20181029,20181106,20181106,EXP,,GH-GILEAD-2018-0372676,GILEAD,,,,A,,Y,,,20181106,,MD,GB,GH,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,155920411,OT,,,,,,,,,155920411,1,HIV infection
15592042,155920421,1,I,,20181029,20181106,20181106,EXP,,GH-GILEAD-2018-0372678,GILEAD,,,,A,,Y,,,20181106,,MD,GB,GH,EFAVIRENZ.,Gene mutation identification test positive;Virologic failure,155920421,OT,,,,,,,,,155920421,1,HIV infection
15592067,155920671,1,I,,20181029,20181106,20181106,EXP,,GH-GILEAD-2018-0372677,GILEAD,,,,A,,Y,,,20181106,,MD,GB,GH,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,155920671,OT,,,,,,,,,155920671,1,HIV infection
15592379,155923791,1,I,,20181031,20181106,20181106,EXP,,GB-GILEAD-2018-0372147,GILEAD,,,,A,F,Y,,,20181106,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kidney infection,155923791,HO,,,,,,,,,155923791,1,Product used for unknown indication
15594088,155940881,1,I,,20181029,20181106,20181106,EXP,,GH-GILEAD-2018-0372681,GILEAD,,,,A,,Y,,,20181106,,MD,GB,GH,EFAVIRENZ.,Gene mutation identification test positive;Virologic failure,155940881,OT,,,,,,,,,155940881,1,HIV infection
15594157,155941571,1,I,201803,20181031,20181106,20181106,EXP,GB-MHRA-ADR 24309488,GB-MYLANLABS-2018M1083151,MYLAN,,,,,M,Y,,,20181106,,MD,GB,GB,EFAVIRENZ.,Blood HIV RNA increased;Drug interaction,155941571,OT,,,,,,,,,155941571,1,Product used for unknown indication
15594255,155942551,1,I,,20181029,20181106,20181106,EXP,,IN-GILEAD-2018-0372053,GILEAD,"BALASWAMY REDDY, GURUPRASAD SRINIVAS. ATYPICAL PSYCHOPATHOLOGY AND CLINICAL CHALLENGES IN TREATING A PATIENT WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER. HIV AND AIDS REVIEW. 17 (3) (PP 224-226), 2018. DATE OF PUBLICATION: 2018. 2018;17, 3::224-226. DOI:DOI.ORG/10.5114/HIVAR.2018.78496",39,YR,A,M,Y,,,20181106,,MD,IN,IN,EFAVIRENZ.,Drug interaction;HIV-associated neurocognitive disorder;Psychotic disorder,155942551,OT,,,,,,,,,155942551,1,HIV infection
15597106,155971061,1,I,,20181029,20181108,20181108,EXP,,UG-HETERO CORPORATE-HET2018UG01164,HETERO,"MAHSA ABASSI, JOSHUA RHEIN, DAVID B. MEYA, AND DAVID R. BOULWARE. CRYPTOCOCCAL DISEASE IN THE ERA OF ?TEST AND TREAT?: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2018;5(1)",45,YR,,M,Y,,,20181108,,OT,UG,UG,Efavirenz+Lamivudine+Tenofovir,Condition aggravated;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,155971061,OT,,,,,,,,,155971061,1,HIV infection
15597754,155977541,1,I,,20181024,20181108,20181108,EXP,,UG-MYLANLABS-2018M1082135,MYLAN,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN-FORUM-INFECT-DIS 2018;5(1):NO PAGINATION.",35,YR,,M,Y,,,20181108,,OT,UG,UG,EFAVIRENZ.,Condition aggravated;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Unmasking of previously unidentified disease,155977541,HO,,,,,,,,,155977541,1,HIV infection
15597755,155977551,1,I,,20181024,20181108,20181108,EXP,,UG-MYLANLABS-2018M1082136,MYLAN,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN-FORUM-INFECT-DIS 2018;5(1):NO PAGINATION.",35,YR,,M,Y,,,20181108,,OT,UG,UG,EFAVIRENZ.,Condition aggravated;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Respiratory failure;Unmasking of previously unidentified disease;Unresponsive to stimuli,155977551,DE,,,,,,,,,155977551,1,HIV infection
15600483,156004831,1,I,,20181028,20181109,20181109,EXP,IE-EMA-20180307-AUTODUP-17080000,IE-ACCORD-091080,ACCORD,,37,YR,A,F,Y,,,20181109,,OT,GB,IE,EFAVIRENZ.,Cushingoid;Drug ineffective;Leukopenia;Off label use;Skin atrophy,156004831,OT,,,,,,,,,156004831,1,Sarcoidosis
15601246,156012461,1,I,,20181026,20181109,20181109,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2018GSK201803,VIIV,"BALASWAMY R G,  SRINIVAS G. ATYPICAL PSYCHOPATHOLOGY AND CLINICAL CHALLENGES IN TREATING A PATIENT WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER. HIV AND AIDS REVIEW. 2018;17(3):224-226",39,YR,,M,Y,,,20181109,,MD,IN,IN,EFAVIRENZ.,Altered state of consciousness;Daydreaming;Disturbance in attention;Illusion;Irritability;Memory impairment;Psychomotor retardation;Psychotic disorder;Sensory disturbance;Slow response to stimuli;Sluggishness;Thinking abnormal;Treatment noncompliance,156012461,OT,,,,,,,,,156012461,1,HIV infection
15602096,156020961,1,I,,20181026,20181109,20181109,EXP,,IN-GLAXOSMITHKLINE-IN2018GSK201803,GLAXOSMITHKLINE,"BALASWAMY R G,  SRINIVAS G. ATYPICAL PSYCHOPATHOLOGY AND CLINICAL CHALLENGES IN TREATING A PATIENT WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER. HIV AND AIDS REVIEW. 2018;17(3):224-226",39,YR,,M,Y,,,20181109,,MD,IN,IN,EFAVIRENZ.,Altered state of consciousness;Daydreaming;Disturbance in attention;Illusion;Irritability;Memory impairment;Psychomotor retardation;Psychotic disorder;Sensory disturbance;Slow response to stimuli;Sluggishness;Thinking abnormal;Treatment noncompliance,156020961,OT,,,,,,,,,156020961,1,HIV infection
15603654,156036542,2,F,20180115,20181213,20181109,20181218,EXP,,FR-MYLANLABS-2018M1084620,MYLAN,,53,YR,,F,Y,76,KG,20181218,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gene mutation identification test positive;Treatment failure;Virologic failure,156036542,OT,,,156036542,1,20100120,20180215,,,156036542,1,HIV infection
15606261,156062611,1,I,,20181105,20181112,20181112,EXP,,MW-HETERO CORPORATE-HET2018MW01308,HETERO,"ELLIS JP, KALATA N, JOEKES EC, KAMPONDENI S, BENJAMIN LA, HARRISON TS, ET AL.. ISCHEMIC STROKE AS A COMPLICATION OF CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: A CASE REPORT 11 MEDICAL AND HEALTH SCIENCES 1103 CLINICAL SCIENCES.. BMC-INFECT-DIS. 2018;18(1):520",38,YR,,M,Y,,,20181112,,OT,MW,MW,Efavirenz+Lamivudine+Tenofovir,Central nervous system vasculitis;Hemiparesis;Immune reconstitution inflammatory syndrome;Ischaemic stroke,156062611,OT,,,,,,,,,156062611,1,HIV infection
15607511,156075111,1,I,,20181031,20181112,20181112,EXP,,MW-MYLANLABS-2018M1084000,MYLAN,"ELLIS JP, KALATA N, JOEKES EC, KAMPONDENI S, BENJAMIN LA, HARRISON TS, ET AL. ISCHEMIC STROKE AS A COMPLICATION OF CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: A CASE REPORT 11 MEDICAL AND HEALTH SCIENCES 1103 CLINICAL SCIENCES. BMC-INFECT-DIS 2018;18(1):520.",38,YR,,M,Y,,,20181112,,OT,MW,MW,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Central nervous system vasculitis;Hemiparesis;Immune reconstitution inflammatory syndrome;Ischaemic stroke;Paradoxical drug reaction,156075111,HO,,,,,,,,,156075111,1,HIV infection
15609108,156091082,2,F,2018,20181213,20181112,20181226,EXP,,UG-MYLANLABS-2018M1084907,MYLAN,,,,,F,Y,3.8,KG,20181226,,OT,UG,UG,TENOFOVIR DF/LAMIVUDINE/EFAVIRENZ TABLETS 300/300/600MG,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy;Sepsis neonatal;Umbilical granuloma,156091082,CA,,,156091082,1,20180518,,,,156091082,1,HIV infection
15609119,156091191,1,I,20180831,20181102,20181112,20181112,EXP,,UG-MYLANLABS-2018M1084914,MYLAN,,31,YR,,F,Y,,,20181111,,CN,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Exposure during pregnancy;Stillbirth,156091191,OT,,,,,,,,,156091191,1,HIV infection
15612790,156127901,1,I,201808,20181102,20181113,20181113,EXP,,ET-JNJFOC-20181103945,JANSSEN,,36,YR,A,M,Y,48,KG,20181113,,MD,ET,ET,EFAVIRENZ W/LAMIVUDINE/TENOFOVIR DISOPROXIL F,Dermatitis exfoliative,156127901,HO,,,156127901,1,20180816,20181031,,,156127901,1,Tuberculosis
15613414,156134141,1,I,,20181108,20181113,20181113,EXP,,GB-TEVA-2018-GB-974808,TEVA,,,,A,,Y,,,20181113,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density abnormal;Glomerular filtration rate decreased;Nervous system disorder;Renal impairment,156134141,OT,,,,,,,,,156134141,1,Product used for unknown indication
15613650,156136502,2,F,2018,20181215,20181113,20181226,EXP,,UG-MYLANLABS-2018M1085392,MYLAN,,,,,M,Y,3.48,KG,20181226,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156136502,CA,,,156136502,1,20180220,,,,156136502,1,HIV infection
15615163,156151631,1,I,,20181103,20181114,20181114,EXP,,UG-HETERO CORPORATE-HET2018UG01326,HETERO,,,,,M,Y,2.9,KG,20181114,,OT,UG,UG,EFAVIRENZ.,Congenital umbilical hernia;Foetal exposure during pregnancy,156151631,OT,,,156151631,1,20180213,20180322,,,156151631,1,HIV infection
15615270,156152702,2,F,,20181211,20181114,20181224,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103626,BRISTOL MYERS SQUIBB,,49,YR,,M,Y,,,20181224,,OT,PT,PT,EFAVIRENZ.,Acute kidney injury;Hepatotoxicity;Tubulointerstitial nephritis,156152702,OT,,,,,,,,,156152702,1,HIV infection
15617418,156174181,1,I,2018,20181105,20181114,20181114,EXP,,UG-MYLANLABS-2018M1086623,MYLAN,,,,I,M,Y,,,20181114,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156174181,OT,,,156174181,1,20180523,,,,156174181,1,HIV infection
15617422,156174222,2,F,,20181207,20181114,20181214,EXP,,UG-MYLANLABS-2018M1086638,MYLAN,,,,N,F,Y,2.93,KG,20181214,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156174222,CA,,,156174222,1,20180510,,,,156174222,1,HIV infection
15617481,156174811,1,I,,20181106,20181114,20181114,EXP,,UG-MYLANLABS-2018M1086627,MYLAN,,,,I,F,Y,,,20181114,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156174811,CA,,,156174811,1,20180510,,,,156174811,1,HIV infection
15617535,156175353,3,F,,20181218,20181114,20181226,EXP,,PHHY2018PT154439,SANDOZ,,49,YR,,M,Y,,,20181226,,OT,PT,PT,EFAVIRENZ.,Acute kidney injury;Hepatotoxicity;Tubulointerstitial nephritis,156175353,OT,,,,,,,,,156175353,1,HIV infection
15617825,156178252,2,F,2018,20181214,20181114,20181226,EXP,,UG-MYLANLABS-2018M1086708,MYLAN,,,,,M,Y,3,KG,20181226,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156178252,CA,,,156178252,1,20180524,,,,156178252,1,HIV infection
15617826,156178261,1,I,,20181107,20181114,20181114,EXP,,UG-MYLANLABS-2018M1086661,MYLAN,,,,,M,Y,2.6,KG,20181114,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156178261,OT,,,156178261,1,20180523,,,,156178261,1,HIV infection
15617827,156178272,2,F,,20181214,20181114,20181226,EXP,,UG-MYLANLABS-2018M1086680,MYLAN,,,,N,M,Y,3,KG,20181226,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Birth mark;Congenital umbilical hernia;Conjunctivitis bacterial;Foetal exposure during pregnancy;Sepsis neonatal,156178272,CA,,,156178272,1,20180409,,,,156178272,1,HIV infection
15617828,156178282,2,F,2018,20181214,20181114,20181226,EXP,,UG-MYLANLABS-2018M1086699,MYLAN,,,,N,M,Y,,,20181226,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156178282,OT,,,156178282,1,20180516,,,,156178282,1,HIV infection
15618298,156182982,2,F,2018,20181214,20181114,20181226,EXP,,UG-MYLANLABS-2018M1086636,MYLAN,,0,YR,,F,Y,,,20181226,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Foetal exposure during pregnancy;Premature baby;Talipes,156182982,OT,,,156182982,1,20180521,,,,156182982,1,HIV infection
15620323,156203233,3,F,,20181215,20181115,20181229,EXP,,UG-HETERO-HET2018UG01334,HETERO,,,,,F,Y,3.6,KG,20181229,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156203233,CA,,,156203233,1,20180312,20180419,,,156203233,1,HIV infection
15620325,156203251,1,I,,20181103,20181115,20181115,EXP,,UG-HETERO CORPORATE-HET2018UG01336,HETERO,,,,N,F,Y,3.12,KG,20181115,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156203251,OT,,,156203251,1,20180301,20180614,,,156203251,1,HIV infection
15620327,156203271,1,I,,20181103,20181115,20181115,EXP,,UG-HETERO CORPORATE-HET2018UG01338,HETERO,,,,,F,Y,3.5,KG,20181115,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156203271,OT,,,156203271,1,20180322,20180615,,,156203271,1,HIV infection
15620496,156204962,2,F,,20181120,20181115,20181203,EXP,,UG-AUROBINDO-AUR-APL-2018-054491,AUROBINDO,,,,N,F,Y,3.1,KG,20181203,,MD,UG,UG,EFAVIRENZ.,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156204962,OT,,,156204962,1,20180301,,,,156204962,1,HIV infection
15621321,156213211,1,I,,20181108,20181115,20181115,EXP,,CA-ABBVIE-18S-028-2554261-00,ABBVIE,,54,YR,,M,Y,,,20181115,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,156213211,OT,,,,,,,,,156213211,1,HIV infection
15621331,156213311,1,I,2018,20181105,20181115,20181115,EXP,,UG-MYLANLABS-2018M1086693,MYLAN,,,,I,F,Y,3.1,KG,20181115,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156213311,OT,,,156213311,1,20121121,,,,156213311,1,Product used for unknown indication
15621334,156213341,1,I,2018,20181105,20181115,20181115,EXP,,UG-MYLANLABS-2018M1086709,MYLAN,,,,I,M,Y,,,20181115,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156213341,OT,,,156213341,1,20180417,,,,156213341,1,HIV infection
15621336,156213362,2,F,2018,20181214,20181115,20181226,EXP,,UG-MYLANLABS-2018M1086706,MYLAN,,,,,M,Y,3.5,KG,20181226,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156213362,CA,,,156213362,1,20180709,,,,156213362,1,HIV infection
15621343,156213431,1,I,2018,20181105,20181115,20181115,EXP,,UG-MYLANLABS-2018M1086698,MYLAN,,0,YR,,M,Y,,,20181115,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156213431,OT,,,156213431,1,20180412,,,,156213431,1,HIV infection
15621345,156213452,2,F,2018,20181214,20181115,20181220,EXP,,UG-MYLANLABS-2018M1086697,MYLAN,,0,YR,,M,Y,3.2,KG,20181220,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156213452,OT,,,156213452,1,20180522,,,,156213452,1,HIV infection
15621346,156213462,2,F,2018,20181214,20181115,20181226,EXP,,UG-MYLANLABS-2018M1086705,MYLAN,,,,N,M,Y,2.7,KG,20181226,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156213462,OT,,,156213462,1,20180523,,,,156213462,1,HIV infection
15621559,156215591,1,I,2018,20181106,20181115,20181115,EXP,,UG-MYLANLABS-2018M1086624,MYLAN,,,,I,F,Y,,,20181115,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156215591,OT,,,156215591,1,20180404,,,,156215591,1,HIV infection
15622123,156221231,1,I,2018,20181109,20181115,20181115,EXP,,UG-MYLANLABS-2018M1086992,MYLAN,,,,I,M,Y,4.2,KG,20181115,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Congenital umbilical hernia;Foetal exposure during pregnancy,156221231,OT,,,156221231,1,20180406,,,,156221231,1,HIV infection
15622136,156221361,1,I,2018,20181109,20181115,20181115,EXP,,UG-MYLANLABS-2018M1086990,MYLAN,,,,I,F,Y,,,20181115,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156221361,CA,,,156221361,1,20180412,,,,156221361,1,HIV infection
15622137,156221371,1,I,,20181109,20181115,20181115,EXP,,UG-MYLANLABS-2018M1086682,MYLAN,,,,I,F,Y,3.2,KG,20181115,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156221371,OT,,,156221371,1,20180607,,,,156221371,1,HIV infection
15622139,156221391,1,I,2018,20181109,20181115,20181115,EXP,,UG-MYLANLABS-2018M1086991,MYLAN,,,,I,F,Y,4.1,KG,20181115,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156221391,OT,,,156221391,1,20180409,,,,156221391,1,HIV infection
15622838,156228382,2,F,2018,20181214,20181115,20181220,EXP,,UG-MYLANLABS-2018M1086642,MYLAN,,0,YR,,F,Y,2.7,KG,20181220,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156228382,OT,,,156228382,1,20180619,,,,156228382,1,HIV infection
15622928,156229282,2,F,2018,20181214,20181115,20181226,EXP,,UG-MYLANLABS-2018M1086707,MYLAN,,,,,F,Y,3.69,KG,20181226,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156229282,OT,,,156229282,1,20180607,,,,156229282,1,HIV infection
15622930,156229301,1,I,2018,20181106,20181115,20181115,EXP,,UG-MYLANLABS-2018M1086629,MYLAN,,,,,M,Y,3.13,KG,20181115,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156229301,CA,,,156229301,1,20180328,,,,156229301,1,HIV infection
15624816,156248162,2,F,,20181205,20181116,20181214,EXP,,UG-CIPLA (EU) LIMITED-2018UG22544,CIPLA,,,,,,Y,,,20181214,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156248162,OT,,,,,,,,,,,
15624884,156248841,1,I,,20181105,20181116,20181116,EXP,,UG-CIPLA (EU) LIMITED-2018UG22542,CIPLA,,,,,,Y,,,20181116,,OT,UG,UG,EFAVIRENZ.,Exposure during pregnancy;No adverse event,156248841,OT,,,156248841,2,20180301,,,,156248841,1,HIV infection
15624935,156249351,1,I,,20181105,20181116,20181116,EXP,,UG-CIPLA (EU) LIMITED-2018UG22538,CIPLA,,,,,,Y,,,20181116,,OT,UG,UG,EFAVIRENZ.,Exposure during pregnancy;No adverse event,156249351,OT,,,156249351,1,20180322,,,,156249351,1,HIV infection
15624972,156249724,4,F,,20181217,20181116,20181227,EXP,,UG-CIPLA (EU) LIMITED-2018UG22536,CIPLA,,,,,,Y,,,20181227,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156249724,CA,,,156249724,1,20180312,,,,,,
15626057,156260572,2,F,,20181214,20181116,20181226,EXP,,UG-MYLANLABS-2018M1086712,MYLAN,,,,,F,Y,3.6,KG,20181226,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156260572,CA,,,156260572,1,20180312,,,,156260572,1,HIV infection
15626058,156260581,1,I,2018,20181102,20181116,20181116,EXP,,UG-MYLANLABS-2018M1086715,MYLAN,,,,I,F,Y,,,20181116,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156260581,OT,,,156260581,1,20180322,,,,156260581,1,HIV infection
15626107,156261072,2,F,2018,20181214,20181116,20181226,EXP,,UG-MYLANLABS-2018M1086700,MYLAN,,,,N,M,Y,,,20181226,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Congenital umbilical hernia;Foetal exposure during pregnancy,156261072,CA,,,156261072,1,20180626,,,,156261072,1,HIV infection
15626574,156265741,1,I,201202,20140715,20181116,20181116,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2014GSK055696,VIIV,,51,YR,,M,Y,,,20181116,,CN,FR,FR,SUSTIVA,Axonal neuropathy;Hypokinesia;Muscular weakness;Pain;Spinal muscular atrophy,156265741,OT,,,156265741,1,2005,20111102,,,156265741,1,HIV infection
15626601,156266011,1,I,,20181108,20181116,20181116,EXP,,CA-ABBVIE-18S-028-2554269-00,ABBVIE,,,,A,M,Y,,,20181116,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,156266011,OT,,,,,,,,,156266011,1,Product used for unknown indication
15626642,156266421,1,I,,20181108,20181116,20181116,EXP,,CA-ABBVIE-18S-028-2554272-00,ABBVIE,,,,,M,Y,,,20181116,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,156266421,OT,,,,,,,,,156266421,1,Product used for unknown indication
15626751,156267512,2,F,,20181108,20181116,20181128,EXP,,CA-ABBVIE-18S-028-2552613-00,ABBVIE,,,,A,M,Y,,,20181128,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,156267512,OT,,,,,,,,,156267512,1,Product used for unknown indication
15627007,156270071,1,I,2018,20181112,20181116,20181116,EXP,,UG-MYLANLABS-2018M1086998,MYLAN,,0,YR,,F,Y,,,20181116,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156270071,CA,,,156270071,1,20180301,,,,156270071,1,HIV infection
15627052,156270521,1,I,,20181108,20181116,20181116,EXP,,CA-ABBVIE-18S-028-2554273-00,ABBVIE,,,,,M,Y,,,20181116,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,156270521,OT,,,,,,,,,156270521,1,Product used for unknown indication
15627054,156270542,2,F,2018,20181214,20181116,20181220,EXP,,UG-MYLANLABS-2018M1086694,MYLAN,,,,,F,Y,3.11,KG,20181220,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156270542,CA,,,156270542,1,20180604,,,,156270542,1,HIV infection
15628175,156281751,1,I,2018,20181109,20181116,20181116,EXP,,UG-MYLANLABS-2018M1086989,MYLAN,,,,I,F,Y,,,20181116,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156281751,CA,,,156281751,1,20180607,,,,156281751,1,HIV infection
15629934,156299341,1,I,,20181108,20181117,20181117,EXP,,UG-MYLANLABS-2018M1086681,MYLAN,,,,I,M,Y,2.8,KG,20181117,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156299341,OT,,,156299341,1,20180503,,,,156299341,1,HIV infection
15630483,156304831,1,I,,20181105,20181119,20181119,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-104504,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20181119,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,156304831,OT,,,,,,,,,156304831,1,HIV infection
15630676,156306763,3,F,,20181217,20181119,20181227,EXP,,UG-CIPLA (EU) LIMITED-2018UG22523,CIPLA,,,,,,Y,,,20181227,,OT,UG,UG,EFAVIRENZ.,Congenital umbilical hernia;Foetal exposure during pregnancy,156306763,OT,,,,,,,,,,,
15630744,156307444,4,F,,20181217,20181119,20181227,EXP,,UG-CIPLA (EU) LIMITED-2018UG22528,CIPLA,,,,,,Y,,,20181227,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156307444,OT,,,,,,,,,,,
15630832,156308321,1,I,,20181105,20181119,20181119,EXP,,MW-CIPLA LTD.-2018MW22677,CIPLA,,,,,,Y,,,20181119,,OT,MW,MW,EFAVIRENZ.,Neutropenia,156308321,OT,,,,,,,,,156308321,1,HIV infection
15635369,156353691,1,I,20180213,20181105,20181120,20181120,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018018671,MACLEODS,,,,,,Y,,,20181120,,OT,US,UG,EFAVIRENZ 600 MG,Foetal exposure during pregnancy;Umbilical hernia,156353691,CA,,,156353691,1,20180213,,,,156353691,1,HIV infection
15635371,156353711,1,I,20180312,20181105,20181120,20181120,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018018666,MACLEODS,,,,,,Y,,,20181120,,OT,US,UG,EFAVIRENZ.,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156353711,OT,,,156353711,1,20180312,,,,156353711,1,HIV infection
15635372,156353722,2,F,20180301,20181205,20181120,20181220,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018018676,MACLEODS,,,,,,Y,,,20181220,,OT,US,UG,EFAVIRENZ 600 MG,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156353722,OT,,,156353722,1,20180301,,,,156353722,1,HIV infection
15635377,156353771,1,I,20180220,20181105,20181120,20181120,EXP,,UG-MACLEODS PHARMACEUTICALS US LTD-MAC2018018685,MACLEODS,,,,,,Y,,,20181120,,OT,UG,UG,EFAVIRENZ 600 MG,Foetal exposure during pregnancy;Umbilical hernia,156353771,OT,,,156353771,1,20180220,,,,156353771,1,HIV infection
15636953,156369531,1,I,,20181107,20181120,20181120,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2018GSK209110,VIIV,"CARDOSO M, BAPTISTA T,  DIOGO I,  ALEIXO MJ, MARQUES N, MANSINHO K. ET AL. TWO CASES OF DOLUTEGRAVIR FAILURE WITH R263K MUTATION. AIDS. 2018;32:2639-2642",29,YR,,F,Y,,,20181120,,OT,PT,PT,EFAVIRENZ + EMTRICITABINA + TENOFOVIR DISOPROXIL,Exposure during pregnancy;Live birth;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,156369531,OT,,,,,,,,,156369531,1,HIV infection
15640518,156405181,1,I,,20181115,20181120,20181120,EXP,,GB-GILEAD-2018-0375288,GILEAD,,,,A,M,Y,,,20181120,,MD,GB,GB,EFAVIRENZ.,Diabetes mellitus;Disease risk factor;Hypertension;Renal impairment,156405181,OT,,,,,,,,,156405181,1,HIV infection
15644174,156441741,1,I,,20181119,20181121,20181121,EXP,,US-GILEAD-2018-0375281,GILEAD,,52,YR,A,M,Y,,,20181121,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pain;Varicose vein,156441741,HO,,,156441741,1,201406,,,,156441741,1,HIV infection
15644814,156448141,1,I,,20171213,20181121,20181121,EXP,,GB-ASPEN-GLO2017GB008586,ASPEN,BRIGHT PD ET AL.. THE TREATMENT OF A PREGNANT HIV POSITIVE PATIENT WITH CRYPTOCOCCAL MENINGITIS IN MALAWI. CASE REPORT AND REVIEW OF TREATMENT OPTIONS. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:9-12,,,,M,Y,1.8,KG,20181121,,OT,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Low birth weight baby;Off label use;Premature baby,156448141,OT,,,,,,,,,156448141,1,Product used for unknown indication
15644840,156448401,1,I,,20181120,20181121,20181121,EXP,,US-GILEAD-2018-0375595,GILEAD,,61,YR,A,M,Y,,,20181121,,CN,US,US,SUSTIVA,Off label use;Pulmonary embolism,156448401,OT,,,156448401,1,20180131,20181116,,,156448401,1,Cor pulmonale
15645742,156457421,1,I,,20181113,20181121,20181121,EXP,,PHHY2018GB161759,SANDOZ,"DAKSHINA S, MILLER RF, TONG CYW, SARNER L. SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS IN PREGNANCY IN AN HIV-POSITIVE WOMAN. INTERNATIONAL JOURNAL OF STD AND AIDS. 2018;29(11):1130-2",39,YR,,F,Y,,,20181122,,OT,GB,GB,EFAVIRENZ.,Foetal death;Maternal exposure during pregnancy;Product use in unapproved indication,156457421,OT,,,,,,,,,156457421,1,HIV infection
15647145,156471451,1,I,,20181112,20181122,20181122,EXP,,MW-AUROBINDO-AUR-APL-2018-055640,AUROBINDO,,38,YR,,M,Y,,,20181122,,OT,MW,MW,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",Asthenia;Central nervous system vasculitis;Headache;Hemiparesis;Immune reconstitution inflammatory syndrome;Ischaemic stroke;Pyrexia,156471451,OT,,,,,,,,,156471451,1,Antiretroviral therapy
15647188,156471882,2,F,,20181122,20181122,20181127,EXP,,UG-STRIDES ARCOLAB LIMITED-2018SP009604,STRIDES,,,,,F,Y,3,KG,20181127,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156471882,CA,,,156471882,1,20180301,,,,156471882,1,Product used for unknown indication
15650108,156501081,1,I,,20181112,20181123,20181123,EXP,,ZA-CIPLA LTD.-2018ZA22897,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. CLINICAL INFECTIOUS DISEASES. 2018;66 (6):921 TO 929",,,,,Y,,,20181123,,OT,ZA,ZA,EFAVIRENZ.,Exposure during pregnancy;Human immunodeficiency virus transmission,156501081,OT,,,,,,,,,156501081,1,Prophylaxis against HIV infection
15650118,156501181,1,I,,20181112,20181123,20181123,EXP,,US-CIPLA LTD.-2018ZA22899,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. CLINICAL INFECTIOUS DISEASES. 2018;66 (6):921 TO 929",,,,,Y,,,20181123,,OT,US,ZA,EFAVIRENZ.,Exposure during pregnancy;Human immunodeficiency virus transmission,156501181,OT,,,,,,,,,156501181,1,HIV infection
15650133,156501331,1,I,,20181112,20181123,20181123,EXP,,ZA-CIPLA LTD.-2018ZA22901,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. CLINICAL INFECTIOUS DISEASES. 2018;66 (6):921 TO 929",,,,,Y,,,20181123,,OT,ZA,ZA,EFAVIRENZ.,Exposure during pregnancy;Human immunodeficiency virus transmission,156501331,OT,,,,,,,,,156501331,1,Prophylaxis against HIV infection
15650510,156505101,1,I,,20181112,20181123,20181123,EXP,,ZA-CIPLA LTD.-2018ZA22900,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. CLINICAL INFECTIOUS DISEASES. 2018;66:921 TO 929",,,,,Y,,,20181123,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Human immunodeficiency virus transmission,156505101,OT,,,,,,,,,156505101,2,Prophylaxis against HIV infection
15650512,156505121,1,I,,20181112,20181123,20181123,EXP,,ZA-CIPLA LTD.-2018ZA22902,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. CLINICAL INFECTIOUS DISEASES. 2018;66 (6):921 TO 929",,,,,Y,,,20181123,,OT,ZA,ZA,EFAVIRENZ.,Dehydration;Foetal exposure during pregnancy;Gastroenteritis;Human immunodeficiency virus transmission,156505121,DE,,,,,,,,,156505121,1,Prophylaxis against HIV infection
15650517,156505171,1,I,,20181112,20181123,20181123,EXP,,ZA-CIPLA LTD.-2018ZA22898,CIPLA,"SALAZAR-AUSTIN N, HOFFMANN J, COHN S, MASHABELA F, WAJA Z, LALA S ET AL.. POOR OBSTETRIC AND INFANT OUTCOMES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT WOMEN WITH TUBERCULOSIS IN SOUTH AFRICA: THE TSHEPISO STUDY. HIV AND TUBERCULOSIS DISEASE IN PREGNANCY. 2018;66:921 TO 929",,,,,Y,,,20181123,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection,156505171,OT,,,,,,,,,156505171,2,Prophylaxis against HIV infection
15652074,156520742,2,F,,20181215,20181123,20181219,EXP,,UG-GILEAD-2018-0373362,GILEAD,,,,N,M,Y,3.48,KG,20181219,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156520742,OT,,,156520742,1,20180220,20180412,,,156520742,1,HIV infection
15652894,156528942,2,F,20180921,20181120,20181123,20181123,EXP,,PHHY2018LS164083,NOVARTIS,,42,YR,,F,Y,51.5,KG,20181123,,MD,LS,LS,EFAVIRENZ.,Aspartate aminotransferase increased;Hypokalaemia;Respiratory failure,156528942,DE,,,156528942,1,20180807,20180629,,,156528942,1,Tuberculosis
15655884,156558842,2,F,,20181215,20181126,20181220,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018213126,VIIV,,,,,M,Y,3,KG,20181220,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156558842,CA,,,156558842,1,20180220,20180412,,,156558842,1,HIV infection
15655906,156559062,2,F,,20181215,20181126,20181220,EXP,,UG-GLAXOSMITHKLINE-UG2018213126,GLAXOSMITHKLINE,,,,,M,Y,3,KG,20181220,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156559062,OT,,,156559062,1,20180220,20180412,,,156559062,1,HIV infection
15657246,156572461,1,I,,20181120,20181126,20181126,EXP,,PHHY2018ET163751,SANDOZ,"ANGAMO MT, CHALMERS L, CURTAIN CM, YILMA D, BEREZNICKI L. MORTALITY FROM ADVERSE DRUG REACTION-RELATED HOSPITALIZATIONS IN SOUTH-WEST ETHIOPIA: A CROSS-SECTIONAL STUDY. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2018;43:790-98",,,,,Y,,,20181126,,OT,AU,ET,EFAVIRENZ.,Hepatotoxicity,156572461,DE,,,,,,,,,156572461,1,Tuberculosis
15657250,156572501,1,I,,20181120,20181126,20181126,EXP,,PHHY2018ET163717,SANDOZ,"ANGAMO MT, CHALMERS L, CURTAIN CM, YILMA D, BEREZNICKI. MORTALITY FROM ADVERSE DRUG REACTION-RELATED HOSPITALIZATIONS IN SOUTH-WEST ETHIOPIA: A CROSS-SECTIONAL STUDY. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2018;43:790-8",,,,,Y,,,20181126,,OT,AU,ET,EFAVIRENZ.,Hepatotoxicity,156572501,DE,,,,,,,,,156572501,1,Product used for unknown indication
15658877,156588772,2,F,2018,20181113,20181126,20181206,EXP,,UG-MYLANLABS-2018M1087630,MYLAN,,39,WK,,F,Y,3.6,KG,20181206,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156588772,CA,,,156588772,1,20180312,,,,156588772,1,HIV infection
15659270,156592702,2,F,,20181215,20181127,20181223,EXP,,UG-STRIDES ARCOLAB LIMITED-2018SP009590,STRIDES,,,,,M,Y,3,KG,20181224,,CN,US,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156592702,CA,,,,,,,,,156592702,1,Product used for unknown indication
15660775,156607751,1,I,20180908,20181121,20181127,20181127,EXP,,ID-JNJFOC-20181129492,JANSSEN,,48,YR,A,M,Y,50,KG,20181127,,MD,ID,ID,EFAVIRENZ.,Blood sodium decreased;Dyspepsia;Haemoglobin decreased;Tuberculosis,156607751,HO,,,156607751,1,20180829,20180908,,,156607751,1,Tuberculosis
15660781,156607811,1,I,2018,20181121,20181127,20181127,EXP,,UG-MYLANLABS-2018M1087718,MYLAN,,,,,M,Y,2.6,KG,20181127,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156607811,CA,,,156607811,1,20180523,,,,156607811,1,HIV infection
15660783,156607831,1,I,2018,20181121,20181127,20181127,EXP,,UG-MYLANLABS-2018M1087713,MYLAN,,,,,M,Y,3.21,KG,20181127,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy;Polydactyly,156607831,CA,,,156607831,1,20180605,2018,,,156607831,1,HIV infection
15660800,156608001,1,I,,20181119,20181127,20181127,EXP,,PT-TEVA-2018-PT-980117,TEVA,SANTOS J. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY. 2018;61(2):64-71.,32,YR,,M,Y,,,20181127,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156608001,OT,,,,,,,,,156608001,2,HIV infection CDC category C
15660824,156608242,2,F,,20181123,20181127,20181205,EXP,,PT-TEVA-2018-PT-980142,TEVA,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY 2018;61(2):64-71.",32,YR,,M,Y,,,20181205,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156608242,OT,,,,,,,,,156608242,2,HIV infection CDC category C
15660861,156608612,2,F,,20181123,20181127,20181205,EXP,,PT-TEVA-2018-PT-980116,TEVA,SANTOS J. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY. 2018;61(2):64-71.,29,YR,,M,Y,,,20181205,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156608612,OT,,,,,,,,,156608612,2,HIV infection CDC category C
15661847,156618471,1,I,2018,20181121,20181127,20181127,EXP,,UG-MYLANLABS-2018M1087721,MYLAN,,,,,F,Y,3,KG,20181127,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156618471,CA,,,156618471,1,20180412,2018,,,156618471,1,HIV infection
15662296,156622961,1,I,2018,20181121,20181127,20181127,EXP,,UG-MYLANLABS-2018M1087695,MYLAN,,0,YR,,M,Y,3.48,KG,20181127,,OT,UG,UG,EFAVIRENZ.,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156622961,OT,,,156622961,1,20180220,,,,156622961,1,Product used for unknown indication
15662329,156623291,1,I,2018,20181121,20181127,20181127,EXP,,UG-MYLANLABS-2018M1087719,MYLAN,,,,,M,Y,3.2,KG,20181127,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156623291,CA,,,156623291,1,20180626,20180814,,,156623291,1,HIV infection
15662443,156624431,1,I,,20181119,20181127,20181127,EXP,,ZA-GILEAD-2018-0376550,GILEAD,"VENTER WDF, KAMBUGU A, CHERSICH MF, BECKER S, HILL A, ARULAPPAN N, MOORHOUSE M, MAJAM M, AKPOMIEMIE G, SOKHELA S, POONGULALI S, FELDMAN C, DUNCOMBE C, BROWN RIPIN DH, KUMARASAMY N. EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS LOW-DOSE STAVUDINE OVER 96 WEEKS: A MULTI-COUNTRY RANDOMISED, NON-INFERIORITY TRIAL. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2018;UNK:UNK. DOI:DOI: 10.1097/QAI.0000000000001908",,,A,,Y,,,20181127,,MD,ZA,ZA,EFAVIRENZ.,Fracture,156624431,OT,,,,,,,,,156624431,1,HIV infection
15662449,156624491,1,I,,20181119,20181127,20181127,EXP,,ZA-GILEAD-2018-0376551,GILEAD,"VENTER WDF, KAMBUGU A, CHERSICH MF, BECKER S, HILL A, ARULAPPAN N, MOORHOUSE M, MAJAM M, AKPOMIEMIE G, SOKHELA S, POONGULALI S, FELDMAN C, DUNCOMBE C, BROWN RIPIN DH, KUMARASAMY N. EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS LOW-DOSE STAVUDINE OVER 96 WEEKS: A MULTI-COUNTRY RANDOMISED, NON-INFERIORITY TRIAL. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2018;UNK:UNK. DOI:DOI: 10.1097/QAI.0000000000001908",,,A,,Y,,,20181127,,MD,ZA,ZA,EFAVIRENZ.,Fracture,156624491,OT,,,,,,,,,156624491,1,HIV infection
15662450,156624501,1,I,,20181119,20181127,20181127,EXP,,ZA-GILEAD-2018-0376552,GILEAD,"VENTER WDF, KAMBUGU A, CHERSICH MF, BECKER S, HILL A, ARULAPPAN N, MOORHOUSE M, MAJAM M, AKPOMIEMIE G, SOKHELA S, POONGULALI S, FELDMAN C, DUNCOMBE C, BROWN RIPIN DH, KUMARASAMY N. EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS LOW-DOSE STAVUDINE OVER 96 WEEKS: A MULTI-COUNTRY RANDOMISED, NON-INFERIORITY TRIAL. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2018;UNK:UNK. DOI:DOI: 10.1097/QAI.0000000000001908",,,A,,Y,,,20181127,,MD,ZA,ZA,EFAVIRENZ.,Fracture,156624501,OT,,,,,,,,,156624501,1,HIV infection
15662452,156624521,1,I,201801,20181120,20181127,20181127,EXP,,US-GILEAD-2018-0375490,GILEAD,,69,YR,E,M,Y,,,20181127,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ocular neoplasm;Product use issue,156624521,OT,,,,,,,,,156624521,1,HIV infection
15662513,156625131,1,I,2018,20181114,20181127,20181127,EXP,,UG-MYLANLABS-2018M1087644,MYLAN,,,,,F,Y,3.2,KG,20181127,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Congenital umbilical hernia;Foetal exposure during pregnancy,156625131,OT,,,156625131,1,20180607,,,,156625131,1,HIV infection
15665943,156659431,1,I,,20181119,20181128,20181128,EXP,,PK-GILEAD-2018-0375884,GILEAD,"TARIQ U, PARVEEN A, AKHTAR F, MAHMOOD F, ALI S, ABIDI S. EMERGENCE OF CIRCULATING RECOMBINANT FORM 56-CPX IN PAKISTAN. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2018;34 (11):1002-1004. DOI:10.1089/AID.2018.0128",29,YR,A,M,Y,,,20181128,,OT,PK,PK,EFAVIRENZ.,Drug ineffective;Genotype drug resistance test positive,156659431,OT,,,,,,,,,156659431,1,HIV infection
15669067,156690672,2,F,,20181215,20181129,20181223,EXP,,UG-STRIDES ARCOLAB LIMITED-2018SP009600,STRIDES,,,,,F,Y,3,KG,20181224,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156690672,CA,,,,,,,,,156690672,1,Product used for unknown indication
15669602,156696021,1,I,,20181121,20181129,20181129,EXP,,UG-MYLANLABS-2018M1087720,MYLAN,,,,I,M,Y,2.7,KG,20181129,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Umbilical hernia,156696021,CA,,,156696021,1,20180523,,,,156696021,1,Product used for unknown indication
15669630,156696301,1,I,2018,20181114,20181129,20181129,EXP,,UG-MYLANLABS-2018M1087639,MYLAN,,,,I,F,Y,2.7,KG,20181129,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156696301,CA,,,156696301,1,20180619,,,,156696301,1,HIV infection
15674687,156746871,1,I,,20181119,20181130,20181130,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112917,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181130,,OT,IN,ZA,EFAVIRENZ.,Lactic acidosis;Prescribed underdose,156746871,OT,,,,,,,,,156746871,1,HIV infection
15674696,156746961,1,I,,20181119,20181130,20181130,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112918,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181130,,OT,IN,ZA,EFAVIRENZ.,Lactic acidosis;Prescribed underdose,156746961,OT,,,,,,,,,156746961,1,HIV infection
15674709,156747091,1,I,,20181119,20181130,20181130,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112919,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181130,,OT,IN,ZA,EFAVIRENZ.,Lactic acidosis;Prescribed underdose,156747091,OT,,,,,,,,,156747091,1,HIV infection
15674772,156747721,1,I,,20181119,20181130,20181130,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112920,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181130,,OT,IN,ZA,EFAVIRENZ.,Lactic acidosis;Prescribed underdose,156747721,OT,,,,,,,,,156747721,1,HIV infection
15677872,156778721,1,I,,20181127,20181130,20181130,EXP,,US-GILEAD-2018-0377165,GILEAD,,73,YR,E,M,Y,,,20181130,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Breast neoplasm,156778721,OT,,,,,,,,,156778721,1,HIV infection
15678006,156780061,1,I,2018,20181115,20181130,20181130,EXP,,UG-MYLANLABS-2018M1089888,MYLAN,,,,,F,Y,2.4,KG,20181130,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Foetal exposure during pregnancy;Talipes,156780061,CA,,,156780061,1,20180521,,,,156780061,1,HIV infection
15681282,156812821,1,I,20171114,20181120,20181203,20181203,EXP,,LS-JNJFOC-20181127370,JANSSEN,,41,YR,A,F,Y,54.7,KG,20181203,,MD,LS,LS,EFAVIRENZ.,Cellulitis;Off label use;Product use in unapproved indication,156812821,HO,,,156812821,1,20171114,20180729,,,156812821,1,Tuberculosis
15681284,156812841,1,I,,20181119,20181203,20181203,EXP,,"PT-ASSERTIO THERAPEUTICS, INC.-PT-2018DEP001919",DEPOMED,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A.. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C.. INTERVIROLOGY. 2018;61(2):64-71",32,YR,,M,Y,,,20181203,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156812841,OT,,,,,,,,,156812841,1,Product used for unknown indication
15681335,156813351,1,I,,20181120,20181203,20181203,EXP,,CA-ABBVIE-18S-028-2576421-00,ABBVIE,,,,,M,Y,,,20181203,,OT,CA,CA,EFAVIRENZ.,Depression;Drug interaction,156813351,OT,,,,,,,,,156813351,1,Product used for unknown indication
15681391,156813911,1,I,2018,20181108,20181203,20181203,EXP,,UG-MYLANLABS-2018M1089630,MYLAN,,,,I,F,Y,4.1,KG,20181203,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Umbilical hernia,156813911,CA,,,156813911,1,20180409,,,,156813911,1,Product used for unknown indication
15681433,156814331,1,I,,20181112,20181203,20181203,EXP,,UG-MYLANLABS-2018M1089620,MYLAN,,,,I,F,Y,3.12,KG,20181203,,OT,UG,UG,EFAVIRENZ.,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156814331,CA,,,156814331,1,20180301,,,,156814331,1,HIV infection
15681499,156814991,1,I,2018,20181126,20181203,20181203,EXP,,UG-MYLANLABS-2018M1089743,MYLAN,,,,I,F,Y,3.6,KG,20181203,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156814991,CA,,,156814991,1,20180312,,,,156814991,1,Product used for unknown indication
15681520,156815201,1,I,20070426,20181121,20181203,20181203,EXP,,JP-GILEAD-2018-0376861,GILEAD,,41,YR,A,M,Y,,,20181203,,OT,JP,JP,EFAVIRENZ.,Autoimmune hepatitis;Hyperlipidaemia,156815201,HO,,,156815201,1,20060526,20060429,,,156815201,1,HIV infection
15682068,156820681,1,I,20180503,20181108,20181203,20181203,EXP,,UG-MYLANLABS-2018M1089629,MYLAN,,0,YR,,M,Y,2.8,KG,20181203,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156820681,CA,,,156820681,1,20180503,,,,156820681,1,HIV infection
15682770,156827701,1,I,,20181128,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113070,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,,,20181203,,MD,GB,GB,EFAVIRENZ.,Lipodystrophy acquired,156827701,OT,,,,,,,,,156827701,1,Product used for unknown indication
15684167,156841671,1,I,,20181121,20181204,20181204,EXP,,ZW-ASTELLAS-2018US050700,ASTELLAS,,36,YR,,F,Y,,,20181204,,CN,GB,ZW,EFAVIRENZ.,Anaemia,156841671,LT,,,156841671,1,20181026,,,,156841671,1,Meningitis cryptococcal
15684612,156846121,1,I,,20181121,20181204,20181204,EXP,,"UG-LANNETT COMPANY, INC.-UG-2018LAN001362",LANNETT,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN-FORUM-INFECT-DIS. 2018;5(1):NO PAGINATION",45,YR,,M,Y,,,20181204,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,156846121,DE,,,,,,,,,156846121,1,Antiretroviral therapy
15684660,156846601,1,I,2018,20181127,20181204,20181204,EXP,,UG-MYLANLABS-2018M1090128,MYLAN,,,,I,F,Y,2.4,KG,20181204,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Foetal exposure during pregnancy;Premature baby;Talipes,156846601,CA,,,156846601,1,20180521,,,,156846601,1,Product used for unknown indication
15684666,156846661,1,I,,20181121,20181204,20181204,EXP,,"UG-LANNETT COMPANY, INC.-UG-2018LAN001363",LANNETT,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN-FORUM-INFECT-DIS. 2018;5(1):NO PAGINATION",35,YR,,M,Y,,,20181204,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,156846661,DE,,,,,,,,,156846661,1,Antiretroviral therapy
15684861,156848611,1,I,,20181121,20181204,20181204,EXP,,"UG-LANNETT COMPANY, INC.-UG-2018LAN001364",LANNETT,"ABASSI M, RHEIN J, MEYA DB, BOULWARE DR. CRYPTOCOCCAL DISEASE IN THE ERA OF ^TEST AND TREAT^: IS THERE CAUSE FOR CONCERN?. OPEN-FORUM-INFECT-DIS. 2018;5(1):NO PAGINATION",,,,,Y,,,20181204,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,156848611,DE,,,,,,,,,156848611,1,Antiretroviral therapy
15685736,156857361,1,I,201610,20180711,20181204,20181204,EXP,,GB-GILEAD-2018-0349731,GILEAD,"SUTTON N, GUPTA N. HIV-POSITIVE WOMEN AND CONTRACEPTION; EFFICACY VERSUS ACCEPTABILITY. HIV MEDICINE. 2018;19(19):S122",38,YR,A,F,Y,,,20181204,,MD,GB,GB,EFAVIRENZ.,Abortion induced;Drug interaction;Pregnancy with implant contraceptive;Unintended pregnancy,156857361,OT,,,,,,,,,156857361,1,Antiretroviral therapy
15692336,156923362,2,F,,20181215,20181205,20181226,EXP,,UG-MYLANLABS-2018M1090123,MYLAN,,,,,M,Y,2.99,KG,20181226,,OT,UG,UG,EFAVIRENZ.,Congenital umbilical hernia;Foetal exposure during pregnancy,156923362,CA,,,156923362,1,20180213,,,,156923362,1,HIV infection
15694155,156941551,1,I,,20181112,20181206,20181206,EXP,,PT-MYLANLABS-2018M1089146,MYLAN,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY 2018;61(2):64-71.",32,YR,,M,Y,,,20181206,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156941551,OT,,,,,,,,,156941551,1,HIV infection CDC category C
15694342,156943421,1,I,,20181112,20181206,20181206,EXP,,PT-MYLANLABS-2018M1089147,MYLAN,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY 2018;61(2):64-71.",29,YR,,M,Y,,,20181206,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156943421,OT,,,,,,,,,156943421,1,HIV infection CDC category C
15695364,156953641,1,I,,20181112,20181206,20181206,EXP,,PT-MYLANLABS-2018M1089143,MYLAN,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY 2018;61(2):64-71.",32,YR,,M,Y,,,20181206,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury,156953641,OT,,,,,,,,,156953641,1,HIV infection CDC category C
15696292,156962921,1,I,,20181123,20181206,20181206,EXP,,PK-MYLANLABS-2018M1088855,MYLAN,"TARIQ U, PARVEEN A, AKHTAR F, MAHMOOD F, ALI S, ABIDI SH. EMERGENCE OF CIRCULATING RECOMBINANT FORM 56-CPX IN PAKISTAN. AIDS-RES-HUM-RETROVIRUSES 2018;34(11):1002-1004.",29,YR,,M,Y,,,20181206,,OT,PK,PK,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Therapeutic response decreased,156962921,OT,,,,,,,,,156962921,1,HIV infection
15696681,156966811,1,I,20150411,20181129,20181206,20181206,EXP,,TH-MYLANLABS-2018M1090876,MYLAN,,30,YR,,F,Y,,,20181206,,OT,TH,TH,EFAVIRENZ MYLAN,Abortion spontaneous;Maternal exposure during pregnancy,156966811,OT,,,156966811,1,20140604,,,,156966811,1,HIV infection
15699383,156993831,1,I,,20181203,20181207,20181207,EXP,,UG-MYLANLABS-2018M1091143,MYLAN,,,,,M,Y,2.87,KG,20181207,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Congenital umbilical hernia;Foetal exposure during pregnancy,156993831,CA,,,156993831,1,20180412,,,,156993831,1,Product used for unknown indication
15699652,156996521,1,I,,20181108,20181207,20181207,PER,,US-009507513-1811USA003665,MERCK,"MORGELLO S, JACOBS M, MURRAY J, BYRD D, NEIBART E, MINTZ L, ET AL. ALZHEIMER?S DISEASE NEUROPATHOLOGY MAY NOT PREDICT FUNCTIONAL IMPAIRMENT IN HIV: A REPORT OF TWO INDIVIDUALS. JOURNAL OF NEUROVIROLOGY. 2018;24(5):629-37",81,YR,,F,Y,,,20181207,,OT,US,US,SUSTIVA,Drug ineffective,,,,,,,,,,,156996521,1,Antiretroviral therapy
15702258,157022581,1,I,,20181126,20181209,20181209,EXP,,PT-AUROBINDO-AUR-APL-2018-058726,AUROBINDO,,32,YR,,M,Y,,,20181210,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Transaminases increased,157022581,OT,,,,,,,,,157022581,1,Hepatitis C
15706512,157065121,1,I,,20181203,20181210,20181210,EXP,E2B_01280806,CA-SA-2018SA331431,SANOFI AVENTIS,,46,YR,A,M,Y,,,20181210,,OT,CA,CA,EFAVIRENZ.,Drug interaction;Transaminases increased,157065121,OT,,,,,,,,,157065121,1,Pulmonary tuberculosis
15708417,157084172,2,F,,20181211,20181211,20181224,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112504,BRISTOL MYERS SQUIBB,,29,YR,,M,Y,,,20181224,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,157084172,OT,,,,,,,,,157084172,1,HIV infection CDC category C
15711389,157113891,1,I,,20181207,20181211,20181211,EXP,,FR-MYLANLABS-2018M1091785,MYLAN,,44,YR,,M,Y,,,20181211,,MD,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR\TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,157113891,OT,,,,,,,,,157113891,1,HIV infection
15719432,157194326,6,F,,20181212,20181213,20181217,EXP,,PHHY2018IN179076,ALCON,"MATHEW T, AVATI A, D^SOUZA D, THERAMBIL M, BAPTIST AA, SHAJI A ET AL. HIV INFECTION ASSOCIATED NEUROMYELITIS OPTICA SPECTRUM DISORDER: CLINICAL FEATURES, IMAGING FINDINGS, MANAGEMENT AND OUTCOMES. MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2018;27:289 ? 3",37,YR,,F,Y,,,20181217,,OT,IN,IN,EFAVIRENZ.,Cushing's syndrome;Pancytopenia,157194326,OT,,,157194326,2,20150213,20150218,,,157194326,1,Neuromyelitis optica spectrum disorder
15721173,157211732,2,F,,20181203,20181214,20181219,EXP,,IN-HETERO LABS LIMITED-HET2018IN01520,HETERO,"BALASWAMY REDDY G, SRINIVAS G.. ATYPICAL PSYCHOPATHOLOGY AND CLINICAL CHALLENGES IN TREATING A PATIENT WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER.. HIV-AIDS-REV.. 2018;17(3):224-226.",39,YR,,M,Y,,,20181219,,OT,IN,IN,EFAVIRENZ.,HIV-associated neurocognitive disorder;Psychotic disorder,157211732,OT,,,,,,,,,157211732,1,HIV infection
15722987,157229871,1,I,,20181210,20181214,20181214,EXP,,FR-MYLANLABS-2018M1092827,MYLAN,,23,YR,,M,Y,,,20181214,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,157229871,OT,,,,,,,,,157229871,1,HIV infection
15725928,157259282,2,F,20171228,20181206,20181216,20181217,EXP,,PHHY2018LS180549,SANDOZ,,57,YR,,M,Y,40,KG,20181217,,CN,LS,LS,EFAVIRENZ.,Diarrhoea;Gastroenteritis;Hepatitis;Hypothyroidism;Incorrect product administration duration;Liver function test increased;Nausea;Peptic ulcer helicobacter;Vomiting,157259282,OT,,,157259282,1,20170713,20181112,,,157259282,1,Tuberculosis
15732856,157328561,1,I,201810,20181212,20181217,20181217,EXP,,ZA-MYLANLABS-2018M1093652,MYLAN,,,,,M,Y,.83,KG,20181217,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Intraventricular haemorrhage neonatal;Neonatal respiratory distress syndrome;Premature separation of placenta,157328561,OT,,,157328561,1,20181003,,,,157328561,1,HIV infection
15736978,157369781,1,I,,20181213,20181218,20181218,EXP,,ZA-MYLANLABS-2018M1094191,MYLAN,,,,,M,Y,3.66,KG,20181218,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cleft palate;Congenital umbilical hernia;Foetal exposure during pregnancy,157369781,OT,,,157369781,1,20180320,,,,157369781,1,Product used for unknown indication
15737481,157374811,1,I,2018,20181213,20181218,20181218,EXP,,ZA-MYLANLABS-2018M1094234,MYLAN,,0,YR,,M,Y,1.85,KG,20181218,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy;Premature baby,157374811,CA,,,157374811,1,20180405,,,,157374811,1,Product used for unknown indication
15743463,157434631,1,I,2013,20181210,20181220,20181220,EXP,,UG-CIPLA LTD.-2018UG23687,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE?: DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181220,,OT,UG,UG,EFAVIRENZ.,Osteomalacia,157434631,OT,,,,,,,,,157434631,1,Antiretroviral therapy
15743464,157434641,1,I,2013,20181210,20181220,20181220,EXP,,UG-CIPLA LTD.-2018UG23685,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE(?): DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181220,,OT,UG,UG,EFAVIRENZ.,Parkinsonism,157434641,OT,,,,,,,,,157434641,1,Antiretroviral therapy
15744828,157448281,1,I,,20181217,20181220,20181220,EXP,,IT-MYLANLABS-2018M1094534,MYLAN,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ET.AL.. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON.. HIV MEDICINE. 2018",,,A,,Y,,,20181220,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,157448281,OT,,,,,,,,,157448281,1,HIV infection
15744833,157448331,1,I,,20181217,20181220,20181220,EXP,,IT-MYLANLABS-2018M1094530,MYLAN,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ET.AL. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON.. HIV MEDICINE.. 2018",,,A,,Y,,,20181220,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,157448331,OT,,,,,,,,,157448331,1,HIV infection
15744865,157448651,1,I,,20181217,20181220,20181220,EXP,,IT-MYLANLABS-2018M1094495,MYLAN,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S ET AL. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE.. HIV MEDICINE. 2018",,,A,,Y,,,20181220,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,157448651,OT,,,,,,,,,157448651,1,HIV infection
15746215,157462151,1,I,,20181214,20181220,20181220,EXP,,ZA-MYLANLABS-2018M1094943,MYLAN,,,,N,F,Y,3.42,KG,20181220,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,157462151,CA,,,157462151,1,20180531,,,,157462151,1,HIV infection
15746229,157462291,1,I,,20181217,20181220,20181220,EXP,,IT-MYLANLABS-2018M1094526,MYLAN,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ET,AL. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON.. HIV MEDICINE.. 2018",,,A,,Y,,,20181220,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,157462291,OT,,,,,,,,,157462291,1,HIV infection
15747240,157472401,1,I,,20181217,20181220,20181220,EXP,,IT-MYLANLABS-2018M1094528,MYLAN,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ET.AL.. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON.. HIV MEDICINE.. 2018",,,A,,Y,,,20181220,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,157472401,OT,,,,,,,,,,,
15747640,157476401,1,I,,20181218,20181220,20181220,EXP,,US-GILEAD-2018-0380897,GILEAD,,47,YR,A,F,Y,,,20181220,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blindness;Fat tissue increased;Hysterectomy,157476401,HO,,,157476401,1,1992,,,,157476401,1,HIV infection
15749989,157499891,1,I,,20181210,20181221,20181221,EXP,,UG-CIPLA LTD.-2018UG23732,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE?: DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181221,,OT,UG,UG,EFAVIRENZ.,Eyelid disorder,157499891,OT,,,,,,,,,157499891,1,Antiretroviral therapy
15749992,157499923,3,F,201312,20181210,20181221,20181224,EXP,,UG-CIPLA LTD.-2018UG23709,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE?: DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181224,,OT,UG,UG,EFAVIRENZ.,Gynaecomastia,157499923,OT,,,,,,,,,157499923,1,Antiretroviral therapy
15749995,157499951,1,I,201804,20181210,20181221,20181221,EXP,,UG-CIPLA LTD.-2018UG23710,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE?: DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181221,,OT,UG,UG,EFAVIRENZ.,Gynaecomastia,157499951,OT,,,,,,,,,157499951,1,Antiretroviral therapy
15749997,157499971,1,I,,20181210,20181221,20181221,EXP,,UG-CIPLA LTD.-2018UG23734,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE(?): DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181221,,OT,UG,UG,EFAVIRENZ.,Aphthous ulcer,157499971,OT,,,,,,,,,157499971,1,Antiretroviral therapy
15751682,157516821,1,I,20180208,20181217,20181221,20181221,EXP,,ZA-GILEAD-2018-0381235,GILEAD,,0,YR,N,M,Y,4.02,KG,20181221,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Strabismus congenital,157516821,CA,,,157516821,1,20180208,,,,157516821,1,HIV infection
15751695,157516952,2,F,,20181224,20181221,20181231,EXP,,ZA-GILEAD-2018-0381253,GILEAD,,,,N,F,Y,,,20181231,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital acrochordon;Foetal exposure during pregnancy,157516952,CA,,,157516952,1,20180524,,,,157516952,1,HIV infection
15752109,157521091,1,I,,20181211,20181221,20181221,EXP,,TG-MYLANLABS-2018M1093926,MYLAN,"SAKA B, AKAKPO AS, BASSOWA A, DAPAM AN, MAHAMADOU G, TECLESSOU JN, ET AL. NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)-INDUCED STEVENS-JOHNSON SYNDROME AND GYNECOMASTIA IN AN HIV-INFECTED CHILD: A CASE REPORT. ANN-DERMATOL-VENEREOL 2018;145(12):773-776.",,,T,M,Y,,,20181221,,OT,TG,TG,EFAVIRENZ.,Gynaecomastia;Stevens-Johnson syndrome,157521091,OT,,,157521091,1,201508,201707,,,157521091,1,HIV infection
15752741,157527411,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381546,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527411,OT,,,,,,,,,157527411,1,HIV infection
15752742,157527421,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381549,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527421,OT,,,,,,,,,157527421,1,HIV infection
15752743,157527431,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381547,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527431,OT,,,,,,,,,157527431,1,HIV infection
15752744,157527441,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381548,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527441,OT,,,,,,,,,157527441,1,HIV infection
15752748,157527481,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381544,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527481,OT,,,,,,,,,157527481,1,HIV infection
15752749,157527491,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381545,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,F,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527491,OT,,,,,,,,,157527491,1,HIV infection
15752755,157527551,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381554,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527551,OT,,,,,,,,,157527551,1,HIV infection
15752756,157527561,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381560,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527561,OT,,,,,,,,,157527561,1,HIV infection
15752757,157527571,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381557,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527571,OT,,,,,,,,,157527571,1,HIV infection
15752758,157527581,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381565,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527581,OT,,,,,,,,,157527581,1,HIV infection
15752765,157527651,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381556,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527651,OT,,,,,,,,,157527651,1,HIV infection
15752766,157527661,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381563,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527661,OT,,,,,,,,,157527661,1,HIV infection
15752767,157527671,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381564,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527671,OT,,,,,,,,,157527671,1,HIV infection
15752768,157527681,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381553,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527681,OT,,,,,,,,,157527681,1,HIV infection
15752769,157527691,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381566,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527691,OT,,,,,,,,,157527691,1,HIV infection
15752770,157527701,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381550,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527701,OT,,,,,,,,,157527701,1,HIV infection
15752772,157527721,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381562,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527721,OT,,,,,,,,,157527721,1,HIV infection
15752773,157527731,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381561,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527731,OT,,,,,,,,,157527731,1,HIV infection
15752774,157527741,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381559,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527741,OT,,,,,,,,,157527741,1,HIV infection
15752775,157527751,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381551,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527751,OT,,,,,,,,,157527751,1,HIV infection
15752778,157527781,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381555,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527781,OT,,,,,,,,,157527781,1,HIV infection
15752779,157527791,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381552,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527791,OT,,,,,,,,,157527791,1,HIV infection
15752780,157527801,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381567,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527801,OT,,,,,,,,,157527801,1,HIV infection
15752781,157527811,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381558,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527811,OT,,,,,,,,,157527811,1,HIV infection
15752783,157527831,1,I,,20181217,20181221,20181221,EXP,,MW-GILEAD-2018-0381507,GILEAD,"DADABHAI S, GADAMA1 L, CHAMANGA R, KAWALAZIRA R, KATUMBR C, DULA D, SINGINJL I, DEGNAN L, KAMANGA M, TAHA T. PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY). IAS-USA TOPICS IN ANTIVIRAL MEDICINE. 2018;UNK:372. DOI:DOI: 10.1097/QAI.0000000000001875",,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157527831,OT,,,,,,,,,157527831,1,HIV infection
15752900,157529001,1,I,,20180430,20181221,20181221,EXP,,MW-GILEAD-2018-0336633,GILEAD,,,,I,,Y,,,20181221,,MD,MW,MW,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157529001,OT,,,,,,,,,157529001,1,HIV infection
15754515,157545151,1,I,2013,20181210,20181224,20181224,EXP,,UG-CIPLA LTD.-2018UG23692,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE?: DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181224,,OT,UG,UG,EFAVIRENZ.,Exposure during pregnancy;Foetal death,157545151,OT,,,,,,,,,157545151,1,Antiretroviral therapy
15754626,157546261,1,I,2014,20181210,20181224,20181224,EXP,,UG-CIPLA LTD.-2018UG23691,CIPLA,"KIGUBA R, NDAGIJE HB, NAMBASA V, BIRD SM. ADVERSE DRUG REACTION ONSETS IN UGANDA^S VIGIBASE(?): DELAYED INTERNATIONAL VISIBILITY, DATA QUALITY AND ILLUSTRATIVE SIGNAL DETECTION ANALYSES. PHARMACEUTICAL MEDICINE. 2018;32:413 TO 427",,,,,Y,,,20181224,,OT,UG,UG,EFAVIRENZ.,Hepatorenal syndrome,157546261,OT,,,,,,,,,157546261,1,Antiretroviral therapy
15758249,157582491,1,I,20070426,20181210,20181225,20181225,EXP,,GB-AUROBINDO-AUR-APL-2018-061061,AUROBINDO,,41,YR,,M,Y,,,20181225,,OT,JP,GB,EFAVIRENZ.,Autoimmune hepatitis;Hyperlipidaemia,157582491,HO,,,157582491,1,20060421,,,,157582491,1,HIV infection
15758812,157588121,1,I,,20181212,20181225,20181225,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-117137,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20181225,,PH,GB,GB,EFAVIRENZ.,Diabetic ketoacidosis;Dysphagia;Malaise;Pneumonia aspiration;Wrong technique in product usage process,157588121,OT,,,,,,,,,157588121,1,HIV infection
15760400,157604001,1,I,2018,20181214,20181226,20181226,EXP,,ZA-MYLANLABS-2018M1095054,MYLAN,,0,YR,,M,Y,4,KG,20181226,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital acrochordon;Foetal exposure during pregnancy,157604001,CA,,,157604001,1,20180412,,,,157604001,1,HIV infection
15763185,157631851,1,I,,20181217,20181226,20181226,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-119901,BRISTOL MYERS SQUIBB,,53,YR,,M,Y,,,20181226,,MD,PT,PT,EFAVIRENZ.,Lipodystrophy acquired,157631851,OT,,,,,,,,,157631851,1,HIV infection
15763192,157631921,1,I,,20181127,20181226,20181226,EXP,,PT-AUROBINDO-AUR-APL-2018-059347,AUROBINDO,,30,YR,,M,Y,,,20181227,,OT,PT,PT,EFAVIRENZ.,Product use in unapproved indication;Seizure,157631921,OT,,,,,,,,,157631921,1,Mycobacterial infection
15763654,157636541,1,I,,20181217,20181227,20181227,EXP,,IN-CIPLA LTD.-2018IN24004,CIPLA,,,,,,Y,,,20181227,,OT,IN,IN,EFAVIRENZ.,Generalised oedema;Periorbital oedema;Proteinuria;Virologic failure,157636541,OT,,,,,,,,,157636541,1,HIV infection
15763787,157637871,1,I,,20181217,20181227,20181227,EXP,,TH-ROCHE-2233996,ROCHE,"KAMPICHIT S, PRATIPANAWATR T AND JARERNSIRIPORNKUL N CONFIDENCE AND ACCURACY IN IDENTIFICATION OF ADVERSE DRUG REACTIONS REPORTED BY OUTPATIENTS. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY 2018 DEC 01;40 (6):1559-1567.",,,,,Y,,,20181227,,OT,TH,TH,EFAVIRENZ.,Alopecia;Angioedema;Arthralgia;Decreased appetite;Diarrhoea;Dizziness;Dry mouth;Face oedema;Fatigue;Flushing;Headache;Muscle spasticity;Myalgia;Nail disorder;Nausea;Oedema peripheral;Paraesthesia;Pruritus;Pyrexia;Rash;Somnolence;Tremor;Vomiting,157637871,OT,,,,,,,,,157637871,1,Product used for unknown indication
15766914,157669141,1,I,,20181213,20181227,20181227,EXP,,IN-MYLANLABS-2018M1094689,MYLAN,"MATHEW T, AVATI A, D^SOUZA D, THERAMBIL M, BAPTIST AA, SHAJI A, ET AL. HIV INFECTION ASSOCIATED NEUROMYELITIS OPTICA SPECTRUM DISORDER: CLINICAL FEATURES, IMAGING FINDINGS, MANAGEMENT AND OUTCOMES. MULT-SCLER-RELAT-DIS 2019;27:289-293.",37,YR,,F,Y,,,20181227,,OT,IN,IN,EFAVIRENZ.,Alopecia;Cushingoid;Mouth ulceration;Pancytopenia,157669141,OT,,,,,,,,,157669141,1,Neuromyelitis optica spectrum disorder
15766916,157669162,2,F,,20181218,20181227,20181228,EXP,,IT-MYLANLABS-2018M1095305,MYLAN,,,,A,,Y,,,20181228,,MD,IT,IT,EFAVIRENZ.,Hepatotoxicity;Toxicity to various agents,157669162,OT,,,,,,,,,157669162,1,HIV infection
15766921,157669212,2,F,,20181218,20181227,20181228,EXP,,IT-MYLANLABS-2018M1095307,MYLAN,,,,A,,Y,,,20181228,,MD,IT,IT,EFAVIRENZ.,Neurotoxicity;Toxicity to various agents,157669212,OT,,,,,,,,,157669212,1,HIV infection
15767297,157672971,1,I,201112,20181220,20181227,20181227,EXP,,GB-GILEAD-2018-0381479,GILEAD,,,,A,M,Y,,,20181227,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Osteoporosis,157672971,OT,,,157672971,1,201112,201810,,,157672971,1,HIV infection
15767908,157679081,1,I,,20181220,20181227,20181227,EXP,GB-MHRA-EYC 00181171,GB-MYLANLABS-2018M1096185,MYLAN,,44,YR,,,Y,,,20181227,,CN,GB,GB,EFAVIRENZ.,Death,157679081,DE,,,,,,,,,157679081,1,HIV infection
15773439,157734391,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382250,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734391,OT,,,,,,,,,157734391,1,HIV infection
15773441,157734411,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382549,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734411,OT,,,,,,,,,157734411,1,HIV infection
15773442,157734421,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382539,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734421,OT,,,,,,,,,157734421,1,HIV infection
15773443,157734431,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382538,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734431,OT,,,,,,,,,157734431,1,HIV infection
15773444,157734441,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382512,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734441,OT,,,,,,,,,157734441,1,HIV infection
15773446,157734461,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382511,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734461,OT,,,,,,,,,157734461,1,HIV infection
15773452,157734521,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382510,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734521,OT,,,,,,,,,157734521,1,HIV infection
15773463,157734631,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382550,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734631,OT,,,,,,,,,157734631,1,HIV infection
15773465,157734651,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382527,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734651,OT,,,,,,,,,157734651,1,HIV infection
15773466,157734661,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382541,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734661,OT,,,,,,,,,157734661,1,HIV infection
15773467,157734671,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382524,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734671,OT,,,,,,,,,157734671,1,HIV infection
15773468,157734681,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382537,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734681,OT,,,,,,,,,157734681,1,HIV infection
15773469,157734691,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382525,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734691,OT,,,,,,,,,157734691,1,HIV infection
15773470,157734701,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382551,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734701,OT,,,,,,,,,157734701,1,HIV infection
15773471,157734711,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382526,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734711,OT,,,,,,,,,157734711,1,HIV infection
15773482,157734821,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382508,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734821,OT,,,,,,,,,157734821,1,HIV infection
15773483,157734831,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382540,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734831,OT,,,,,,,,,157734831,1,HIV infection
15773484,157734841,1,I,,20181221,20181228,20181228,EXP,,ZA-GILEAD-2018-0382548,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20181228,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Foetal growth restriction,157734841,OT,,,,,,,,,157734841,1,HIV infection
15773855,157738551,1,I,,20181214,20181229,20181229,EXP,,DE-AUROBINDO-AUR-APL-2018-063436,AUROBINDO,,52,YR,,F,Y,,,20181229,,OT,DE,DE,EFAVIRENZ.,Acute psychosis,157738551,OT,,,,,,,,,157738551,1,Product used for unknown indication
15774737,157747371,1,I,,20181218,20181230,20181230,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2018-09039,LUPIN,,38,YR,,M,Y,,,20181230,,OT,ZA,ZA,EFAVIRENZ + LAMIVUDINE + TENOFOVIR;EFAVIRENZ W/LAMIVUDINE/ZIDOVUDINE,Drug resistance;Tuberculosis,157747371,OT,,,157747371,1,200905,20080401,,,157747371,1,Tuberculosis
15774738,157747381,1,I,,20181218,20181230,20181230,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2018-09125,LUPIN,,36,YR,,F,Y,,,20181230,,OT,ZA,ZA,EFAVIRENZ.,Drug resistance;Tuberculosis,157747381,HO,,,157747381,1,201106,20080630,,,157747381,1,Tuberculosis
15774739,157747391,1,I,,20181218,20181230,20181230,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2018-09123,LUPIN,,32,YR,,M,Y,,,20181230,,OT,ZA,ZA,EFAVIRENZ.,Drug resistance;Tuberculosis,157747391,OT,,,157747391,1,,20080320,,,157747391,1,Tuberculosis
15774740,157747401,1,I,,20181218,20181230,20181230,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2018-09126,LUPIN,,30,YR,,F,Y,,,20181230,,OT,ZA,ZA,EFAVIRENZ + LAMIVUDINE + TENOFOVIR;EFAVIRENZ.,Drug resistance;Tuberculosis,157747401,HO,,,157747401,1,201107,20060102,,,157747401,1,Tuberculosis
15774741,157747411,1,I,201004,20181218,20181230,20181230,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2018-09124,LUPIN,,38,YR,,F,Y,,,20181230,,OT,ZA,ZA,EFAVIRENZ.,Drug resistance;Tuberculosis,157747411,HO,,,157747411,1,,20070820,,,157747411,1,Tuberculosis
15775420,157754201,1,I,20060629,20181217,20181231,20181231,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-119832,BRISTOL MYERS SQUIBB,,46,YR,,M,Y,50,KG,20181231,,OT,GB,GB,SUSTIVA,Body temperature increased;Hypotension;Hypoxia;Liver function test abnormal;Malaise;Oxygen saturation decreased;Tachycardia;Tachypnoea;Traumatic lung injury,157754201,HO,,,157754201,1,20060628,20060629,,,157754201,1,HIV infection
15775439,157754391,1,I,,20181217,20181231,20181231,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-122012,BRISTOL MYERS SQUIBB,,,,,,Y,,,20181231,,OT,IN,IN,EFAVIRENZ.,CD4 lymphocytes decreased,157754391,OT,,,,,,,,,157754391,1,HIV infection
15776367,157763671,1,I,20180920,20181229,20181231,20181231,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK233646,VIIV,,23,YR,,M,Y,65,KG,20181231,,OT,CN,CN,STOCRIN (EFAVIRENZ),Hepatic function abnormal;Liver injury;Product use in unapproved indication,157763671,OT,,,157763671,1,20180920,,,,157763671,1,Acquired immunodeficiency syndrome
15776474,157764741,1,I,20180920,20181229,20181231,20181231,EXP,,CN-GLAXOSMITHKLINE-CN2018GSK233646,GLAXOSMITHKLINE,,23,YR,,M,Y,65,KG,20181231,,OT,CN,CN,STOCRIN (EFAVIRENZ),Hepatic function abnormal;Liver injury;Product use in unapproved indication,157764741,OT,,,157764741,1,20180920,,,,157764741,1,Acquired immunodeficiency syndrome
6049025,604902515,15,F,20060216,20181023,20060519,20181102,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13375589,BRISTOL MYERS SQUIBB,,25,YR,,F,Y,56,KG,20181102,,OT,FR,FR,SUSTIVA,Abortion induced;Insomnia;Maternal exposure during pregnancy;Vertigo,604902515,OT,,,604902515,1,20050523,20050908,,,604902515,1,HIV infection
6264473,62644734,4,F,20061129,20181101,20070319,20181112,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13714431,BRISTOL MYERS SQUIBB,,1,DY,,F,Y,,,20181112,,OT,FR,FR,SUSTIVA,Exomphalos;Foetal exposure during pregnancy,62644734,DE,,,62644734,1,,20061019,,,62644734,1,Product used for unknown indication
6927324,69273246,6,F,20050813,20181029,20090304,20181109,EXP,,FR-GILEAD-2009-0020445,GILEAD,,,,,F,Y,1.19,KG,20181109,,OT,FR,FR,SUSTIVA,Arnold-Chiari malformation;Brain herniation;Foetal exposure during pregnancy;Foetal malformation;Spina bifida,69273246,OT,,,69273246,1,20050523,20060216,,,69273246,1,HIV infection
6927327,69273275,5,F,20050813,20181106,20090304,20181112,EXP,,FR-GILEAD-2009-0020444,GILEAD,,25,YR,A,F,Y,56,KG,20181112,,OT,FR,FR,SUSTIVA,Abortion induced;Insomnia;Maternal exposure during pregnancy;Vertigo,69273275,HO,,,69273275,1,20050523,20050908,,,69273275,1,HIV infection
7756177,77561775,5,F,,20181012,20110111,20181022,EXP,,GB-PFIZER INC-2011004396,PFIZER,"SYKES, C.. SUDDEN UNEXPLAINED DEATH IN A PATIENT WITH HIV AND MDR-TB. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2010;13(SUPPL 4):198-198",25,YR,,M,Y,,,20181022,,OT,GB,GB,EFAVIRENZ.,Arrhythmia;Sudden death,77561775,DE,,,,,,,,,77561775,1,Oral candidiasis
7961721,79617213,3,F,,20181031,20110429,20181115,EXP,ADR 21022252-002,GB-ACCORD-008830,ACCORD,"WOODCOCK H, NELSON M. BURKITT^S NON-HODGKINS LYMPHOMA PRESENTING AS FACIAL NERVE PALSY IN HIV-POSITIVE PATIENTS. INTERNATIONAL JOURNAL OF STD + AIDS. 2011;22:112 TO 114.",55,YR,,M,Y,,,20181115,,OT,GB,GB,EFAVIRENZ.,Off label use;Toxicity to various agents,79617213,DE,,,,,,,,,79617213,1,Burkitt's lymphoma
8260766,82607667,7,F,2006,20181023,20111123,20181102,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15921299,BRISTOL MYERS SQUIBB,,,,,F,Y,1.19,KG,20181102,,OT,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal malformation;Spina bifida,82607667,CA,,,82607667,1,20050523,20050908,,,82607667,1,Product used for unknown indication
